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Vitamin D is known to benefit skeletal bone health and prevent rickets in 
children. Limited evidence exists to support a role of vitamin D in linear growth 
and stunting, especially in children at high risk for growth faltering, e.g. 
undernourished low socio-economic status children <5 years.  Also, it is unclear if 
the immunomodulatory benefits of vitamin D impact childhood pneumonia. It is 
critical to determine whether vitamin D ameliorates stunting and pneumonia, as 
these conditions are responsible for a high burden of child mortality and 
morbidity.  
A secondary analysis of two studies in Ecuador was undertaken to 
determine the prevalence of vitamin D deficiency and the effect of vitamin D 
status on growth (height-for-age (HAZ) and weight-for-age (WAZ) z-scores) 
(n=516) and illness duration in children hospitalized for severe pneumonia 
(n=348). Serum 25-hydroxyvitamin D (25(OH)D) concentrations of children who 
participated in a community-based trial (ages 6-36 months) and hospital-based 
trial (ages 2-59 months) were determined at baseline.   
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Overall, 18.6% of children had serum 25(OH)D levels <17 ng/ml (n=516), 
62.2% were stunted (HAZ≤-2), and 65.5% were underweight (WAZ≤-1). Children 
with 25(OH)D concentrations <17 ng/ml had a higher risk of stunting (HAZ≤-2) 
than those with concentrations ≥17 ng/ml (ORadj: 2.8; 95%CI: 1.6, 4.7) in logistic 
regression models. Underweight (WAZ≤-1) children were twice as likely to have 
25(OH)D concentrations <17 ng/ml than normal weight children (WAZ>-1) (ORadj: 
2.0; 95%CI: 1.2,3.3).  
Vitamin D deficiency (≤20 ng/ml) did not affect pneumonia duration among 
hospitalized children in Cox proportional hazard models (HRadj: 1.2; 95% CI: 
0.93,1.5). Younger children (2-12 months), underweight children (WAZ≤-2), and 
children with higher respiratory rates had a longer duration of illness (HRadj: 0.61; 
95% CI: 0.43,0.86; HRadj: 0.78; 95% CI: 0.59,1.0; HRadj: 0.97; 95% CI: 0.96,0.99, 
respectively). 
Underweight Ecuadorian children are at increased risk for lower serum 
25(OH)D concentrations.  Low vitamin D status is associated with stunting 
among undernourished children but not with the duration of pneumonia illness. 
This indicates that vitamin D may be a modifiable risk factor for stunting, which, if 
validated in further research, can potentially impart beneficial effects on growth 
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       CHAPTER ONE 
      INTRODUCTION 
It is often said that location is everything, and when it comes to vitamin D 
research this is highly relevant. Humans obtain nearly 80% of their vitamin D 
from exposure to ultraviolet rays (UV) of sunlight1,2. Geography is linked to 
latitude, altitude, zenith angle of the sun, and air pollution which are all 
inherently linked to the ultraviolet rays reaching the earth’s atmosphere. 
Geographical location fundamentally affects exposure to solar radiation and 
potential vitamin D production.  
 
Quito, the capitol of Ecuador, is the source of the study population that this 
body of research encompasses.  Ecuador has four major geographical regions 
with differing altitudes and climates, the Pacific lowlands, the Andean 
highlands (Sierra), the eastern lowlands (Amazon) and the Galapagos 
Islands3. Quito sits on the Andean foothills with an equatorial latitude (0.23oS) 
and a high altitude at 2,850 meters. Although Ecuador has made gains in terms 
of its Human Development Index (HDI), ranking 88th in the 2015 United Nations 
Human Development Report, it persistently reports high rates of chronic 
malnutrition in children under the age of 5 years.   
 
Stunting, an indicator of chronic malnutrition, is defined as a height-for-age z 




reference population4, and measures the accumulated effect of inadequate 
nutrient intake and/or repeated episodes of diarrhea and infectious disease5.  
A nationally representative demographic and social survey conducted in 2004, 
ENDEMAIN (Encuesta de Demografía y de Salud Materna e Infantil), showed 
a high rate of stunting in children under the age of 5 years. In fact, the major 
nutritional problem that Ecuador suffers from is stunting. Ecuador has a 
stunting prevalence of 23.2% (299,000 children) in children under 5 y of age. 
Of these, 5.9% (77,095 children) are severely stunted (HAZ <-3 SD)3. The 
prevalence of underweight children (weight-for-age z (WAZ) scores <-2 SD 
below the median of the reference population)4,5, which refers to low body 
mass for chronological age, is less at 9.3% and wasting (weight-for-height z 
(WHZ) scores <-2 SD below reference population)4,5,  an indicator of acute 
malnutrition and occurs when a child is thin for his/her height but not 
necessarily short, is low at only 1.7%. This indicates that the deficiencies found 
in weight-for-age are almost entirely a result of stunting5,6.  The trend of high 
stunting and a lower prevalence of underweight and wasting is in line with the 
global international experience6.  
 
Given these factors, Ecuador provides a distinctive backdrop to study vitamin 
D status and its influence on undernutrition, growth, and pneumonia.  This 
chapter will provide a review of vitamin D in part I; Part II and III will provide a 




with malnutrition and pneumonia; Part IV will discuss the vitamin D status in 
Latin America; and Part V will discuss the goals and objectives of this 
dissertation.  
 
PART I: VITAMIN D OVERVIEW 
SOURCES OF VITAMIN D  
 
Sunlight: The major source of vitamin D 
Sunlight is a major source of vitamin D for humans1,2,7. Ultraviolet B (UVB) 
radiation from the sun, with wavelengths of 290 - 315 nanometers (nm), is 
responsible for cutaneous synthesis of vitamin D.  These wavelengths are 
absorbed by 7-dehydrocholeterol (7-DHC)8,9, the precursor to vitamin D.  The 
greatest concentration of 7-DHC is found in the skin’s epidermal layer in the 
inner most epidermal strata, the stratum basale and stratum spinosum7.  7-
DHC contains 4 rings with an unsaturated B ring from two double bonds on the 
5 to 6 and 7 to 8 carbon (5, 7, conjugated diene) (Figure 1-1). When 7-DHC 
absorbs UVB radiation, the addition of energy causes the electrons to become 
excited, causing the bond length to expand8. The torsional strain weakens this 
bond and it undergoes photolysis to form the thermodynamically unstable 
isomer, previtamin D3.  Previtamin D3 isomerizes to vitamin D3 or with further 











There are several factors which influence the amount of UVB exposure 
reaching the earth’s surface10. One of the most important factors is the zenith 
angle of the sun, which is a function of time, season (day of the year), and 
latitude10,11.   As the Earth rotates around the sun, and the seasons change, 
the tilt of the Earth causes the angle at which the sun reaches the Earth’s 
surface to shift11.  As the sunrays hit the Earth at an increased angle, the UV 
radiation needs to traverse a longer distance to cross the Earth’s ozone layer 
causing an increased absorption of UVB by the ozone. These changes in the 
UVB levels reaching the Earth’s surface are responsible for the seasonal 





7-dehydrocholesterol Previtamin D3  







A series of experiments which exposed ampoules containing 7-DHC in ethanol 
at various latitudes (Edmonton, Canada (52oN), Boston, MA (42.2oN), Los 
Angeles (LA), CA (34oN) and Puerto Rico (PR) (18oN) throughout the day and 
measured the percent conversion of 7-DHC to previtamin D3 and other 
photoproducts nicely demonstrated the effect of latitude on the photosynthesis 
of previtamin D31.  In Edmonton, there was no photosynthesis of previtamin D3 
between October and March.  The complete absorption of UVB rays during the 
winter season in areas greater than 35o latitude result in too little UVB to 
produce vitamin D3  - a phenomenon commonly termed as the vitamin D 
winter1.  In contrast, the lower latitudes of LA and PR showed that 
photosynthesis of photoproducts during winter months still occurred in 
January1. The efficiency of conversion of photoproducts was much higher in 
PR (10% conversion) compared to LA (3% conversion) during exposure to 
noon-time sunlight, indicating that a lower latitude in the winter months yields 
to higher conversion of photoproducts.  
 
The effect of altitude on UVB exposure deserves special attention given the 
high altitude where this study was conducted.  A study using the ampoule 
model described above1 was performed at various altitudes in India and Nepal 
with a constant latitude of  27oN with varying altitudes from 169 m in Agra to 




(at 169 m), the efficiency of conversion of 7-DHC to photoproducts at the base 
camp of Mount Everest (5350 m) during noon-time sunlight was nearly 400% 
greater (Figure 1-2). In Lukla, which is at an altitude comparable to Quito’s at 
2860 m, the level of conversion was nearly 200% higher than that of Agra.  
Figure 1-2: % conversion of 7-DHC to photoproducts at varying 
altitudes with constant latitude (27oN) 
 
*Reproduced with permission from Holick et al. JBMR. 200712 
 
A similar experiment was carried out in Quito Ecuador and Boston MA during 
November 2011 (Appendix 1). In this experiment, ampoules were set out 




showed that although Quito experiences 12 hours of daylight per day, there is 
no production of vitamin D after 4 pm confirming that vitamin D can only be 
produced between 7 am to 4 pm, even at the equator (Figure A1-1). Further, 
during November, Ecuadorian residents are still capable of producing vitamin 
D while those in Boston are not able to and have greater conversion efficiency 
than a lower altitude country such as Saudi Arabia during the same period. 
Further, the conversion efficiency during what is considered the ‘wet season’ 
in Ecuador is greater than that in Boston during the summer solstice months. 
 
To understand the capacity of the sun in producing vitamin D, one full body 
minimal erythemal dose (MED) of UVB, defined as turning the skin pink, is 
equivalent to producing nearly 20,000 international units (IU) of vitamin D313 
(Figure 1-3).  Since sunlight is a key source of vitamin D, scientist have 
recommended sensible sun exposure as a source of vitamin D13.     
 
Dietary sources: Limited foods contain vitamin D 
Another source of vitamin D is diet. Vitamin D can be found in a few foods from 
animal, plant, yeast, and fungal sources. Vitamin D3, also known as 
cholecalciferol, is the form of vitamin D obtained from animal sources. Vitamin 
D2, also known as ergocalciferol, is the form of vitamin D obtained from yeast, 




both vitamin D2 and vitamin D3 unless otherwise specified. Animal sources 
naturally enriched with vitamin D include cod liver oil (1360 IU/1 tablespoon), 
wild caught salmon (447 IU/3 ounces), tuna (154 IU/3 ounces) and egg yolk 
(41 IU)14 (Figure 1-3).   An excellent natural source of vitamin D is sundried or 
UV exposed mushrooms (9-493 IU/84 grams).   Figure 1-3 shows the content 
of vitamin D in different foods.  Although these are estimates of the vitamin D 
content in foods, variability does exist. For example there are major differences 
in the vitamin D content of farm raised versus wild caught salmon14.   
 
There are several countries which also fortify foods with vitamin D. Foods 
commonly fortified with vitamin D include milk, infant formula, orange juice, 
cereal, margarine, and bread. Of these, dairy products tend to be the largest 
source of vitamin D15,16. Food fortification rarely exceeds 100 IU per serving. 
Ecuador, the country of focus for this current body of research, does not fortify 
its dairy products with vitamin D although there is a minor amount of vitamin D 
fortification in margarine (2000-4000 IU/kg)17,18, which is equivalent to 28 IU in 
a 1 tablespoon (14 g) serving size.  This is not nearly enough vitamin D to 
reach the dietary reference intake of 600 IU/day in children >12 months old as 






Figure 1-3: Vitamin D content from UVB exposure, naturally occurring 




*Adapted from: Holick et al. The Journal of Clinical Endocrinology and Metabolism. 
2011; 96:1911-30.19 
 
Further evidence exists to suggest that the diet in Ecuador is deficient in vitamin 
D20–22. The traditional diet in Ecuador relies heavily on cereals, which are not 
fortified with vitamin D, and starchy foods20. Staple foods include grains (such as 
barley), tubers (especially potatoes), and fava beans (habas)3. Less than 1% of 
the total energy intake from fish and seafood and <10% from other animal 
sources20 (Figure 1-4). A study which examined the dietary intakes of the elderly 
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of Quito22, which are the same neighborhoods that the children participating in this 
study reside in, found that their diets were 98.2% below the dietary reference range 
of vitamin D based on the 2000 IOM guidelines. The results of dietary intake 
reported in the elderly showed a mean of only 1 µg (40 IU) per day (range 0.0 – 
12 µg). These results are further corroborated by low dietary intakes of vitamin D 
among adults aged 20 to 60 years (n=110) residing in the more coastal central 
region of Ecuador (specifically Guayaquil, Quevedo and El Empalme)21.  
 
Figure 1-4: % of total energy intake by different food groups in 1996-98 
survey in Ecuador* 
 
 
*Based on data presented in the 2001 food and agricultural organization 
nutritional country profile.20 Data presented are from a 1996-98 survey. 
 
 
Ecuador does not have specific guidelines for dietary reference intake (DRI) of 
vitamin D21. The guidelines set forth by the IOM23 in the United States (U.S.) 
recommend a dietary intake of 600 (15 µg) IU/day in children above the age of 1 
year and adequate intakes for infants <12 months (400 (10 µg) IU/day).  Given the 















limited foods and quantity of vitamin D which occur naturally, it is apparent that 
dietary intake alone is inadequate to satisfy an individual's daily vitamin D 
requirement. In fact, an analysis of children’s dietary intake in the U.S., which does 
fortify food with vitamin D24, reported that children were not able to achieve their 
recommended dietary allowance (RDA) for vitamin D from dietary sources alone15.  
Based on the Third National Health and Nutrition Examination Survey, 1988 - 1994 
(NHANES III) children aged 1 to 3 years and 4 to 8 years consumed 5.7 ± 0.09 
µg/d and 6.0 ± 0.10 µg/d respectively with similar results found in the 1994 -1996 
Continuing Survey of Food Intakes by individuals and the 1998 Supplemental 
Survey (CSFII 1994 - 1996, 1998). A more recent analysis found that <2% of 
Americans and Canadians surveyed (n=7837 and n=4025, respectively) met the 
2011 RDA requirements16. A systematic review however found that consuming 
fortified foods (especially milk) resulted in individuals consuming a mean intake of 
440 IU/day (11 µg/d) from fortified foods which corresponded to a mean increase 
of 7.7 ng/ml (95% CI: 5.6, 10.0 ng/ml) in serum 25(OH)D concentrations25.   
 
Supplementation 
An additional source which is an effective method to obtain vitamin D is through 
supplementation. Vitamin D can be taken daily, weekly, or in a bolus dose of high 
levels of vitamin D in 6 or 12 month intervals.  There are two forms of vitamin D 




from irradiating ergosterol from yeast and fungi. Vitamin D3 supplements are made 
by UVB irradiation of 7-DHC that is obtained from the chemical conversion of 
cholesterol extracted from an oily wax (lanolin) found in sheep’s wool26.  Although 
this can be a major source of vitamin D, it is not applicable to the population under 
study here, as the subjects were not supplemented with vitamin D.    
RISK FACTORS FOR VITAMIN D DEFICIENCY VARY 
Two key factors in producing previtamin D3 from sun exposure are the quantity 
(intensity) and quality (wavelength) of the UVB radiation that the skin is exposed 
to11. Behavioral and individual characteristics, which limit the quantity or quality of 
UVB radiation, are important risk factors for vitamin D deficiency. These include 
limited time spent outdoors; spending time indoors from 10 am to 3 pm which are 
the peak times for vitamin D production27;  residing at latitudes >35o during winter 
months as the zenith angle with which the sun hits earth allows little UVB to 
penetrate the ozone1; increased skin pigmentation which has higher melanin levels 
that absorb UVB rays thus preventing them from penetrating into the epidermal 
layer and thereby converting 7-DHC to previtamin D328; sunscreen use which limits 
UV rays from penetrating the skin (it is estimated that an sun protection factor 
(SPF) of 30 can inhibit vitamin D production by 95 - 99%13); air pollution which can 
absorb UV rays27; covering skin due to weather or cultural practices; a decrease 
in 7-DHC in the epidermis (<20 µg/cm2 of skin) which often occurs during aging13.  





Similarly, factors that limit dietary intake or dietary absorption of vitamin D are 
another set of important risk factors for vitamin D deficiency. Exclusively breastfed 
infants are at a high risk of vitamin D deficiency since very little vitamin D is present 
in breast milk13; individuals who are obese are at high risk of vitamin D deficiency 
since fat cells can store vitamin D; not consuming foods fortified with vitamin D 
such as milk; not ingesting any vitamin D supplements (especially in the winter 
months); and fat malabsorption since vitamin D is lipid soluble. Finally, other risk 
factors include specific disease states such as cystic fibrosis and inflammatory 
bowel disease13.   
 
Since the prevalence of vitamin D deficiency has not been established in Andean 
children <5 years of age, the sources of vitamin and risk factors for vitamin D 
deficiency are important to understand.  Children living in the Ecuadorian Andes 
are assumed to have adequate UVB radiation as they reside at equatorial latitudes 
and high altitudes.  However, they can still be at risk of vitamin D deficiency as 
there are several risk factors to which they are exposed to including air pollution, 
low dietary intake, darker skin pigmentation, propensity to cover young children, 
breastfeeding, and lack of supplementation. Given these potential risk factors, a 
hypothesis in this dissertation is that vitamin D deficiency is prevalent among the 
young children in this study population and therefore the magnitude of deficiency 






Table 1-1: Risk factors for vitamin D deficiency 
 
Risk factors Modifiable risk factor 
Limiting UVB conversion of 7-DHC to 
previtamin D 
 
Limited time outdoors Yes 
Being indoors between 10 am - 3 pm Yes 
Covering skin by clothing Yes 
Sunscreen use Yes 
Dark skin pigmentation No 
Decreased 7-DHC No 
Limited UVB radiation  
>35o latitude during winter months No 
Air pollution No 
Risk factors due to limited dietary intake of 
vitamin D 
 
Little dietary vitamin D intake Yes 
No supplementation use Yes 
Exclusive breast feeding infants Yes 
Fat malabsorption No 
Physiological reasons  
Obesity Yes 
Cystic fibrosis No 
 
 
METABOLISM OF 25-HYDROXYVITAMIN D TO 1,25-  
DIHYDROXYVITAMIN D  
The discussion up to this point has focused on vitamin D, a biologically inactive 
metabolite. Vitamin D undergoes a series of metabolic hydroxylations 
converting it to its active form, 1,25-dihydroxyvitamin D [1,25(OH)2D] (Figure 
1-5). Once vitamin D is photosynthesized in the skin, it is no longer sterically 
favorable for it to remain embedded in the phospholipid bilayer and it is 




capillary bed of the skin where it binds to vitamin D binding protein (DBP).  
When vitamin D is consumed, it is transported through the lymphatic system 
to the circulation and subsequently carried to the liver by binding to DBP13,26. 
Both vitamin D2 and vitamin D3, whether obtained from the diet or sun 
exposure, undergo the same activation process29. In the liver, a hydroxyl group 
is attached to form 25-hydroxyvitamin D (25(OH)D).  The 25(OH)D is the major 
circulating form and is used as the primary indicator of supply or status in an 
individual13,26. 25(OH)D is biologically inactive and must undergo additional 
hydroxylation in the renal proximal tubule by the action of the 1-alpha-
hydroxylase (CYP27B1) enzyme to form the active hormonal metabolite, 1,25-
dihydroxyvitamin D [1,25(OH)2D]13,26 (Figure 1-5).  The renal metabolite, first 
identified by Holick in 1971, acts on target cells by binding to its nuclear 
receptor, the vitamin D receptor (VDR).   
 
The VDR is a transcription factor which modulates the expression of genes 
which in turn initiates its physiological effects on bone, small intestine, kidneys 
and more than 2000 other genes that are known to be regulated or modulated 
by the active metabolite13.  The VDR upon binding to 1,25(OH)2D forms a 
heterodimer with retinoid X receptors (RXR). It then binds to special sequences 
in the promoter region of the gene (known as the vitamin D response elements 





Production of 1,25(OH)2D in the kidney is controlled by a negative feedback 
loop from calcium, phosphate, and fibroblast growth factor 23 (FGF 23), and is 
stimulated by PTH.  Extra-renal production of 1,25(OH)2D is controlled 
primarily by cytokines30.  
Figure 1- 5: Metabolism of vitamin D (D represents both D2 and D3) to 
form the active metabolite 1,25-dihydroxyvitamin D 
 
ACTIONS OF VITAMIN D 
 
Vitamin D increases calcium and phosphorus absorption 
It is important to appreciate the actions of vitamin D during a state of vitamin D 
sufficiency so that the consequences of vitamin D deficiency can be 
understood.  The classical role of 1,25(OH)2D is to maintain calcium (Ca2+) and 
phosphorus ion homeostasis29,31 to ensure sufficient levels are maintained for 
bone remodeling. Bone is continuously in a process of being remodeled. To 
maintain normal bone mass, bone is in a state of equilibrium between bone 















formation and bone resorption, although in children the state of rapid growth 
gives bone formation the upper hand. Bone is composed of both organic and 
inorganic components. The major component of bone is inorganic 
hydroxyapatite, a hard mineral formed by Ca2+ and phosphate (PO43-) 
combining with hydroxide (OH-). Hydroxyapatite (Ca5(PO4)3(OH), a hexagonal 
crystal, is formed from 5 calcium and 3 phosphate ions and makes up nearly 
70% of the weight of bone. The organic component of bone is composed of 
collagen and matrix proteins (such as osteocalcin, osteonectin and 
osteopontin). The array of proteins is known as the osteoid and is laid down by 
osteoblasts.   
 
First, 1,25(OH)2D acts to maintain calcium and phosphorus stores to ensure 
there is enough of these minerals for bone formation.  To maintain serum 
calcium levels, 1,25(OH)2D binds to its nuclear receptor in the enterocytes of 
the small intestine. The 1,25(OH)2D-VDR complex acts on the brush border 
membrane to increase the expression of at least 3 genes that aid in absorption 
of dietary calcium and phosphorus. 1,25(OH)2D induces the epithelial calcium 
selective channel TRPV6 (also called ECAC2) to actively uptake calcium from 
the lumen of the small intestine, primarily in the duodenum32.  It also increases 
the transcription of calbindin D9k to facilitate movement of calcium through the 
cytoplasm.  In VDR knock-out mice, calbindin D9k is markedly reduced33. 




(PMCA1b) on the baso-lateral membrane to facilitate active extrusion of the 
calcium from the enterocyte34.  
 
In parallel, 1,25(OH)2D stimulates the absorption of phosphate to maintain 
phosphate homeostasis. It also acts on the small intestine, particularly the 
jejunum and ileum, to enhance the efficiency of absorption of phosphorus13. 
 
So that calcium and phosphorus are not lost in urine, 1,25(OH)2D has also 
been shown to increase the efficiency of reabsorption of calcium in the renal 
proximal tubule by inducing genes which facilitate the transcellular movement 
of calcium.  The kidney plays an especially important role in regulating the 
reabsorption of inorganic phosphate (Pi). The proximal tubule is the major site 
of Pi reabsorption. In both the kidneys and small intestine, the transport of Pi 
is mediated through a sodium dependent cotransporter at the apical side of 
renal cells and enterocytes35,36.  The sodium phosphate type II (NPT2) 
cotransporter, which exists in three isoforms, is responsible for the 
reabsorption of Pi and regulated by PTH and vitamin D.  The NPT2a (type IIa) 
(also known as SLC34A1) and NPT2c (type IIc) are expressed in the kidneys, 
although the messenger RNA (mRNA) for NPT2bc is less abundant than 2a.  
The renal cotransporters are regulated by 1,25(OH)2D and fibroblast growth 
hormone 23 (FGF23). Fibroblast growth hormone 23 (FGF23), secreted by 




In a vitamin D deficient state, it is estimated that only 10-15% of calcium is 
absorbed from the diet and nearly 50-60% of phosphorus can be absorbed21.   
  
Serum ionized calcium is maintained within a very narrow range between 1.0 
- 1.3 nM13. To maintain this serum physiological level, any change in calcium 
levels induces 1,25(OH)2D to act on bone. In the event of low serum calcium, 
1,25(OH)2D interacts with its receptor on osteoblast cells in bone37. This 
causes a cascade of events mediated through the nuclear factor kappa B 
ligand (RANKL) to cause maturation of preosteoclasts to form mature 
osteoclasts37. Osteoclasts are responsible for bone resorption which break 
down the bone matrix to release calcium and phosphorus in to the 
bloodstream.  
 
Thus, in the vitamin D deficient state, when insufficient calcium is absorbed 
from the diet, the calcium in bone is broken down and the calcium-phosphorus 
matrix is not formed.  Low circulating calcium levels cause the serum calcium 
sensors on the parathyroid gland to induce the production of parathyroid 
hormone (PTH)13,26.  Overproduction of PTH, secondary to vitamin D 
deficiency, is a state referred to as secondary hyperthyroidism. PTH has 
deleterious effects on bone since it acts directly on bone to resorb bone to 
release calcium in the serum and concomitantly increases the urinary loss of 




causing the bone mineralization defects that are commonly observed in severe 
vitamin D deficient status such as rickets in children.  Further, vitamin D 
deficiency can cause muscle weakness and effect the normal functioning of 
the diaphragm and intercostal muscles38. With muscle weakness, clearing of 
respiratory secretions may be impaired and this can lead to lower respiratory 
tract infections (LRTI). 
 
A mechanism for stunting due to vitamin D deficiency 
In order for bone growth to occur, calcium and phosphate are required to form 
hydroxyapatite. Beyond this, bone growth also requires mineralization of the 
matrix. In long bone growth, cartilage is present at the endochondral growth 
plate39. Specialized cells within the endochondral growth plate, known as 
chondrocytes, proliferate and secrete the matrix which undergoes 
mineralization39. The mature chondrocytes are then removed by phosphate 
induced apoptosis40. Without apoptosis of chondrocytes at a rate that is equal 
to chondrocyte proliferation, the growth plate will not develop appropriately and 
can thus cause stunting39.  
 
To understand the connection between vitamin D deficiency and poor growth, 
it is important to understand the three stages of rickets40, as this can be a 






Rickets is a disease which manifests in children and is characterized by gross 
bone deformities, poor growth, and stunting in children41. It has been 
recognized for centuries that severe clinical vitamin D deficiency (<12 ng/ml) 
is associated with nutritional rickets41,42.  The first stage of rickets is clinically 
silent.  Vitamin D deficiency causes decreases in intestinal absorption and 
renal reabsorption which in turn causes transient hypocalcemia resulting in an 
increase in the serum PTH levels. As described previously, secondary 
hyperparathyroidism causes increases in calcium absorption by stimulation of 
1,25(OH)2D but also increased excretion of phosphate. The second stage of 
rickets occurs when calcium levels are normalized by the action of PTH to 
stimulate 1-alpha-hydroxylase and increase osteoclastic activity. This results 
in normalization of serum calcium levels and hypophosphatemia (low inorganic 
phosphate).  Without adequate inorganic phosphate, the chondrocytes can no 
longer undergo the phosphate-induced apoptosis of terminally differentiated 
chondrocytes39. As the chondrocytes accumulate due to lack of apoptosis, the 
bones increase in volume39. As a result, the clinical signs of rickets begin to 
appear, including widening of the epiphyseal plates of the long bone, which 
can cause stunting, and at the ribcage causing the rachitic rosary, as well as 





Although there are various causes of rickets, the inability to have chondrocyte 
apoptosis is common to all types of rickets40. In the third stage of rickets, 
25(OH)D concentrations are so low that 1,25(OH)2D levels become very low 
even with PTH stimulation of the renal 1-alpha hydroxylase. Now, intestinal 
calcium absorption is reduced, and mobilization of calcium from the skeleton 
is low, therefore, the PTH induced osteoclasts can no longer sustain serum 
calcium levels.  
 
PTH levels are thought to plateau at levels 25(OH)D ≥30 ng/ml19; therefore, 
this is a very plausible mechanism of action for subclinical vitamin D deficiency 
to cause stunting in children without nutritional rickets.  A proposed mechanism 
for stunting in vitamin D deficient children is that a rise in PTH levels, secondary 
to low vitamin D status, causes increased excretion of phosphate. This results 
in an inadequate calcium-phosphate product needed for the matrix to 
mineralize and inhibition of chondrocyte apoptosis impedes growth in long 
bones, thereby leading to stunting. 
 
NON-CLASSICAL ROLE: EXTRA-RENAL PRODUCTION OF 1,25-
DIHYDROXYVITAMIN D 
A key discovery in the field is that many cells in the body have the 1-alpha-
hydroxylase enzyme and thus the capacity to hydroxylate 25(OH)D to produce 




D43,44. In addition, most tissues and cells in the body contain the VDR. The 
VDR is present in all immune cells including antigen-presenting cells (APCs) 
(e.g. macrophages and dendritic cells), neutrophils, B cells and T cells (CD4+ 
and CD8+)45,46. This breakthrough paved the way to understanding the 
immune modulating function of vitamin D45,47 and how a vitamin D deficient 
state leads to less available 25(OH)D for immune cells to be able to fight 
infection30.   
 
Vitamin D boosts the innate immune response 
The innate immune response is the body’s first line of defense against bacteria, 
viruses, protozoa, and fungi48. Receptors, such as toll-like receptors (TLRs), 
expressed by cells in the innate immune response can recognize molecular 
patterns, known as pathogen-associated molecular patterns (PAMPs)49, that 
are conserved among different classes of pathogens. Binding of the TLRs to 
the microbial ligands induces an antimicrobial response through the release of 
antimicrobial peptides cathelicidin.  The role of vitamin D in this cascade of 
events was elucidated by Liu et al. in a series of experiments which showed 
that binding of the TLRs to microbial ligands, in cells infected with 
Mycobacterium tuberculosis, causes both increased expression of both 1-
alpha hydroxylase and VDR in the immune cell44.  25(OH)D is converted to the 
active metabolite 1,25 (OH)2D and binds to its nuclear receptor which in turn 




antimicrobial peptide (hCAP-18) (which is cleaved to form its active peptide 
form, LL-37) and α and β-defensin30,43,44,47 (Figure 1-6). Cathelicidin is stored 
in large quantities in neutrophils and macrophages, and to a lesser extent in 
monocytes, lymphocytes, respiratory cells, and gastrointestinal cells48,50. 
 
Figure 1-6: Schematic of 25(OH)D conversions to 1,25(OH)2D in an 





Vitamin D modulates the adaptive immune response 
Once the TLRs activate APCs, the APCs present the antigens to T and B 
cells45. Inactive T and B cells do not express the VDR but the levels increase 
once they become activated51. The T and B lymphocytes also have an 




25(OH)D to 1,25(OH)2D30. The 1-alpha hydroxylase is not regulated by PTH; 
however its activity is dependent on circulating levels of 25(OH)D30. 
 
The T cells differentiate into T helper cells (Th1, Th2) which in turn release 
cytokines which bind to the antigen45. The variation in responses to Th1 and 
Th2 is determined by the cytokines they release45 and vitamin D has been 
shown to influence the phenotype expression of CD4+ effector T cells. Th1 
cytokines are pro-inflammatory and initiate a cell-mediated response by 
releasing interleukin-2 (IL-2), gamma interferon (IFN γ), and tumor necrosis 
factor (TNF-α). On the other hand, Th2 is anti-inflammatory and begins an 
antibody-mediated response by releasing the interleukins IL-3, IL-4, IL-5, and 
IL-1045. 1,25(OH)2D is known to decrease pro-inflammatory cytokines whilst 
increasing anti-inflammatory cytokines52. It does so by inhibiting TNF-α, 
suppressing T and B lymphocyte proliferation, and promoting antibody 
apoptosis30,45,51. 1,25(OH)2D favors the Th2 cytokine phenotype and thus it 
modulates the immune system by being anti-inflammatory52. Further, vitamin 
D promotes the formation of T regulatory cells (Tregs)30 which function to 
resolve infection and diminish an excessive immune response47. Supporting 
its role as anti-inflammatory, 1,25(OH)2D also inhibits monocytes from 





It is important to understand the mechanism of action of vitamin D on immune 
function because the current work investigates the role that vitamin D status 
plays on the duration of pneumonia illness. Having a more potent innate 
immune response as well as shifting the adaptive immune response to be more 
anti-inflammatory may be associated with less severity of pneumonia in 
children who have higher levels of vitamin D at the time of hospital admission 
and therefore a shorter time to remission of respiratory signs. 
 
Vitamin D receptor (VDR) polymorphism may be a risk factor for 
disease 
A growing body of evidence shows that VDR polymorphisms due to single 
nucleotide polymorphisms are associated with bone, immune, and 
autoimmune diseases13,53,54. The VDR gene product is a ligand activated 
transcription factor and the gene is located on chromosome 12q12-q1453. 
There are several gene variants that have been found. Taql and Bsml are two 
gene variants which occur at the 3’ end of the VDR gene. These variants 
impact the VDR gene transcription which results in lower VDR activity. Another 
common polymorphism, Fokl, causes polymorphism in the translation initiation 
start codon of VDR55.  The VDR gene has two sites of translation initiation 
coded as ATG.  In one polymorphism, the first translation start codon is coded 
as ACG causing translation to begin at the second translation site55. In another 




the first start codon.  The f allele indicates the presence of the first start codon 
and the F indicates its absence53. Thus, the T or f allele results in the translation 
of a VDR that is 3 amino acids longer than the C or F allele.  Functionally, it 
has been shown that the shorter VDR (with f or T) is less active than longer 
VDR (with C or F)55.  Some studies have found that certain polymorphisms in 
VDR are associated with more severe respiratory disease53 and lower bone 
mineral density55.  
 
Current vitamin D cut-points are debated and may not applicable to all 
outcomes 
In the vitamin D literature, there are several controversies that exist. The first 
is the serum 25(OH)D cutoff used to define deficiency19,23,56,57. The second is 
whether vitamin D2 and vitamin D3 are equally effective in raising 25(OH)D 
levels58–62.  Although circulating levels of 25(OH)D are the accepted measure 
of vitamin D status, which level constitutes deficiency has been very much 
debated.  The two main guidelines which discuss vitamin D status are the 
IOM23 and the Endocrine Society Practice Guidelines19. 
 
The 2011 guidelines by the IOM23 recommend a dietary intake of 600 IU/day 
for children aged 1 to 18 years and adults aged 18 to 70 years. They also 
recommend a slightly higher intake of 800 IU/day in the elderly (>70 years). 




(<12 months) and advised adequate intakes of 400 IU/day in this age group. 
The IOM stated that although 25(OH)D concentration is an excellent measure 
of vitamin D status, yet it is not a biological outcome. This is reflected in the 
language used by defining lower levels of 25(OH)D as a measure of risk. The 
revised clinical definitions are as follows: Individuals with circulating 25(OH)D 
levels <12 ng/ml (<30 nmol/L) are considered at risk of deficiency; those with 
levels <16 ng/ml (40 nmol/L) are at risk of inadequacy. This 25(OH)D 
concentration corresponds to an estimated average vitamin D intake of 400 IU 
daily; while sufficiency was defined >20 ng/ml (50 nmol/L) as this corresponds 
to a 600 IU/day recommended daily allowance for vitamin D which meets the 
requirement of 97.5% of the population.  
 
The Endocrine Society Practice Guidelines have noted that the 600 IU/day 
recommended by the IOM cannot raise and maintain 25(OH)D levels in 
deficient individuals (<20 ng/ml)19.  The Endocrine Society Practice Guidelines 
maintain that levels below 20 ng/ml are defined as deficient. Individuals with 
serum 25(OH)D concentrations between 20 to 29 ng/ml are categorized as 
insufficient, while sufficiency is obtained at the optimal level of ≥30 ng/ml (≥75 
nmol/L).  The daily recommended requirements set forth by the Endocrine 
Society Practice Guidelines are higher than those recommended by the IOM. 




children (1 to 18 years) require 600 - 1000 IU/day and all adults need between 
1500 - 2000 IU/day.  
 
The differences in definitions (Table 1-2) between these two bodies are 
primarily due to the clinical outcomes that are considered to establish each cut-
point.  The Endocrine Society Practice Guidelines report that prior research 
has shown that secondary hyperthyroidism, a state which is deleterious to 
bone health, is attenuated at a serum concentration ≥30 ng/ml19 and that 
optimum skeletal bone mineral density and musculoskeletal health occurs at 
25(OH)D levels >20 ng/ml.  The IOM cutpoints focus on 25(OH)D 
concentrations that are associated with improved bone health (increased 
calcium absorption and prevention of osteomalacia in adults and rickets in 
children)23. 
 
To add to the complexity, there are no specific cutoffs for children due to limited 
research. Many studies use either the pre-set cutoffs established by the IOM23 
or the Endocrine Society Practice Guidelines19 for all ages since insufficient 
data are available to recommend cutoffs specific to the pediatric population. 
Nonetheless, it is worth noting that the traditional cutoffs are set for specific 
outcomes that may not be applicable to the outcome under question63,64. Given 
that there are no set cutoffs for children and the traditional cutoffs used are 




pneumonia, a sensitivity analysis was performed in the current work to 
determine a study-specific 25(OH)D cut-off for each outcome studied. 
 
Table 1-2: Definitions of vitamin D status as defined by the Institute of 
Medicine and the Endocrine Society Practice Guidelines 
 
Institute of Medicine23 Endocrine Society 
Practice Guidelines19 
At risk of deficiency 
 < 12 ng/ml 
 < 30 nmol/L 
Deficiency 
  ≤ 20 ng/ml 
 ≤ 50 nmol/L 
 
At risk of inadequacy 
 < 16 ng/ml  
 < 40 nmol/L 
Insufficiency 
 21-29 ng/ml 
 52.5-72.5 nmol/L 
 
Sufficiency 
 ≥ 20 ng/ml 
 ≥ 50 nmol/L 
 
Sufficiency 
 ≥ 30 ng/ml 
 ≥ 75 nmol/L 
 
 
PART II: VITAMIN D AND GROWTH 
Micronutrient deficits (hidden hunger) are one component captured under the 
umbrella term of malnutrition. Malnutrition also encompasses protein and 
energy deficits and overnutrition65.  Here I will focus on undernutrition. Vitamin 
D deficiency is a one of the most common micronutrient deficiencies 
worldwide66–68. It is estimated that nearly 1 billion children and adults worldwide 





 One of the most important causes of child mortality is malnutrition70. Nearly 
45% of deaths totaling 3.1 million per year71 can be attributed, either directly 
or indirectly, to undernutrition in children younger than 5 years71,72. 
Undernutrition in children, especially stunting, impedes physical and cognitive 
growth, which can impact education, school performance, and intelligence6,73. 
Additionally, the interrelation between undernutrition and infectious disease 
has been well established. The effects of childhood malnutrition can have an 
impact into adulthood6; stunted children have lower productivity when they 
become adults. This has obvious economic consequences at the individual 
and social level6, and is often related to a cyclical, intergenerational cycle of 
poverty and undernutrition. 
 
In the past decade, great progress has been made especially in the context of 
the 1990 to 2015 Millennium Development Goals (MDGs). However, the most 
recent estimates of undernutrition indicate that there is still more to do in the 
new post-2015 Sustainable Development Goals. In children under 5 years, 
nearly 165 million children are still stunted, 101 million are underweight, and 
52 million are wasted71,72,74.  
 
Ecuador has experienced a decline in the prevalence of stunting and 
underweight from the first national nutrition survey in 1986 (DANS 1986; 




Población Menor de Cinco Años) to the most recent 2012 nutritional survey 
(ENSANUT-Ecu 2012; ENSANUT: Encuesta Nacional de Salud y Nutrición- 
Ecuador). The prevalence of children under the age of 5 years who are 
underweight decreased from 12.8% in the 1986 survey to 6.4% in the 2012 
survey75. Stunting rates in 1986 surveys were nearly 40.2% which decreased 
to 25.3%75. Indigenous populations have the highest prevalence of stunting 
(42.3%) and underweight (9.7%) in comparison to other ethnic groups in 
Ecuador75.  Like the DANS 1986 nutrition survey and ENDEMAIN 2004 survey, 
the newest national survey, ENSANUT 2012, found that children in rural 
regions in all areas of Ecuador have a higher prevalence of stunting compared 
to those residing in urban areas (38.4% vs. 27.1% respectively)75. Despite 
efforts by Ecuador’s Ministry of Health, such as the 2011 ‘Desnutrición Cero’ 
(Zero Malnutrition)75, which aims to eliminate malnutrition in children under 2 
years,  there is still a long way to go. 
 
Since stunting has major public health implications, and its prevalence is 
especially high in countries with limited resources, it is necessary to investigate 
nutritional interventions that can improve stunting rates in children. Several 
other micronutrient deficiencies are risk factors for stunting and micronutrient 
interventions shown to improve linear growth are now recommended as one of 
several key nutrition interventions in infants and young children71: The most 




children. Several meta-analyses have shown a positive effect of zinc on linear 
growth in children under 5 years76–78. The largest meta-analysis was 
comprised of 36 studies conducted in developing countries76. That study found 
that a dose of 10 mg/day for 24 weeks resulted in a significant increase in 
length by a mean of 0.37 ± 0.25 cm in young children, with an effect size of 
0.13 (95% CI: 0.04, 0.21)76.   
 
Multiple micronutrient (MMN) interventions have also shown small but 
significant improvements in height (effect size: 0.13; 95% CI: 0.055, 0.21) and 
weight (effect size: 0.23; 95% CI: 0.18, 0.4379). Although studies have found 
that vitamin A and stunted growth are correlated80, the evidence from 
randomized controlled trials (RCTs) does not support a role of vitamin A on 
growth81.  A meta-analysis82 with 14 trials (n=73757) showed that vitamin A 
was not associated with increased height (effect size: -0.08; 95% CI: -0.2 0.36) 
or weight gain (effect size: -0.01; 95% CI:-0.24, 0.22).  
 
These findings indicate that micronutrient nutritional interventions can have an 
important contribution in reducing stunting rates. The role of vitamin D on 
stunting warrants further investigation since there is a clear mechanism of 
action for its effect on skeletal growth. It is believed that vitamin D deficiency 
in rickets contributes to stunting.  Vitamin D deficiency rickets, as well as type 




vitamin D receptor activity respectively, prevent the active 1,25(OH)2D 
hormone  from exerting its role on calcium and phosphorus homeostasis, and 
all have been shown to be associated with stunting40,41,83. Further, treating 
children diagnosed with rickets with vitamin D has also been shown to have a 
positive effect on their growth83,84.  
 
The effect of vitamin D in improving growth parameters beyond the scope of 
rickets has largely been overlooked. Given global efforts to reduce stunting, 
and the well-established mechanisms linking vitamin D with skeletal growth, it 
is important to investigate if vitamin D is an additional micronutrient that can 
have a beneficial effect on growth, especially among undernourished children.  
 
LITERATURE REVIEW OF VITAMIN D AND GROWTH 
ANTHROPOMETRICS IN CHILDREN 
Early childhood is a time of rapid bone growth. In a state of vitamin D 
deficiency, poor mineralization of the skeleton can occur, especially in the long 
bone epiphyses and costochondral junctions41, as previously described. It 
follows logically that because vitamin D is intricately related to skeletal 
development, vitamin D deficiency may result in short stature in children who 
do not have nutritional rickets. The following section provides an overview of 
the literature examining the association between vitamin D and growth. Table 




effect of vitamin D status or supplementation on growth in children less than 
12 years. 
 
INCONCLUSIVE EVIDENCE TO SUGGEST A ROLE OF GESTATIONAL 
VITAMIN D ON INFANT BIRTHWEIGHT AND LENGTH 
Several observational studies and supplementation trials have examined the 
effect of maternal vitamin D status on birth anthropometric measurements85,86. 
Maternal vitamin D levels during gestation are considered to reflect fetal 
vitamin D status, since maternal vitamin D is the only source of vitamin D for 
the fetus86.  A high correlation between maternal vitamin D status and cord 
blood has been demonstrated81,82.  It is thought that maternal vitamin D 
deficiency leads to impaired fetal growth, since fetal bone development 
accrues at a rate of nearly 250 mg of Ca2+ per day in the third trimester87. 
Further, one theory is that the environment in utero may affect early skeletal 
development and the trajectory of growth throughout the lifespan85.  Research 
on the effects of vitamin D in infants (<1 year) and fetal growth has thus 
focused primarily on maternal vitamin D status, and intervention trials usually 
supplement mothers during gestation rather than during the postpartum or 
lactation period.  
 
Although the vast majority of observational studies found no association 




some studies have noted significant differences97–99.  Further, one study 
conducted among Canadian infants found that 25(OH)D cord blood 
concentrations <15 ng/ml had a higher, rather than lower, birth weight and 
length than those with serum levels ≥15 ng/ml100.  Many of the observational 
studies did not control for important confounders such as gestational age88,89,95 
or maternal gestational weight gain88–91,95,97. In addition, several studies did not 
directly measure maternal or fetal 25(OH)D levels93,97. Of those studies that 
did measure serum 25(OH)D levels, some measured concentrations during the 
early stages of pregnancy99, while others did so during the third trimester or 
upon delivery89–92,95.  
 
Intervention studies that supplemented mothers during pregnancy have not 
been definitive either85,86; however dosing and timing varied between studies. 
As Moon and colleagues85 note, studies that supplemented mothers with both 
vitamin D and calcium have shown beneficial effects on birth anthropometric 
measurements compared with those that supplemented mothers with only 
vitamin D.    
 
Several researchers have theorized that the divergent results found between 
various studies may be due to high maternal 25(OH)D concentrations at 




leading to null findings85,87,101. For example, an observational study conducted 
in West Africa92 compared 125 maternal-infant pairs using a cutoff of 32 ng/ml 
(80 nmol/L). None of the subjects showed serum 25(OH)D levels <20 ng/ml 
(<50 nmol/L) and only 20% had serum levels <32 ng/ml. Not surprisingly, they 
found no significant associations between maternal 25(OH)D concentration 
and infant anthropometric measurements92. The high levels of serum 25(OH)D 
and the low percentage of women in the lower cutoffs may explain the null 
findings. To respond to this, a recent study conducted in Iran, recruited 
pregnant women with baseline serum 25(OH)D levels <30 ng/ml, and reported 
significantly higher birth weight (p=0.01), birth length (p=0.001), and head 
circumference (p=0.001) in infants born to supplemented mothers (50,000 IU 
vitamin D3 plus 200 mg Ca2+ and a multivitamin with 400 IU D3) compared to 
controls (supplemented with only 200 mg Ca2+ and a multivitamin with 400 IU 
D3)102. 
 
Because maternal vitamin D status is the only source of vitamin D for the fetus, 
and because birth weight and length set the trajectory of growth in children, it 






VITAMIN D MAY BE ASSOCIATED WITH INCREASES IN LAZ IN 
INFANTS (<1 YEAR) 
As the Multicentre Growth Reference Study (MGRS)103 has shown, healthy 
infants grow at a very similar trajectory despite varying ethnicities and genetic 
factors such as parental weight and height. Deviations from this trajectory can 
occur due to health and nutritional factors. Deficits in growth - or growth 
faltering, especially in the first 1000 days of life - have been associated with 
undernutrition, which includes micronutrient deficiencies.  There are only a 
handful of studies that have examined the association between vitamin D and 
growth parameters in young infants.    
 
Hyppönen et al.104 used a large cohort from the Northern Finland Birth Cohort 
1966 (NFBC 1966) (n=10,821) to determine if vitamin D intake in infants is 
associated with growth. The recommended daily intake for vitamin D in Finland 
during this time was 2000 IU/d (50 µg). Children were categorized as having 
regular daily intakes of ≥2000 IU of vitamin D, irregular intakes (<2000 IU/d), 
or none. The mean unadjusted heights at 1 year of age were significantly 
higher in children with higher vitamin D intake versus those without daily intake 
(p=0.005). However, after adjusting for birth weight, gestational age, and 




significant (p=0.34). They also reported no difference in height at 1 year or at 
14 years in children suspected to have rickets (p=0.78 in both age groups). 
 
Although this was a large cohort, several methodological issues limit the quality 
of this study. Mothers reported the frequency of vitamin D intake over a one 
year period, which may be influenced by the intake patterns in the few months 
before the questionnaire rather than the pattern of intake throughout the year 
due to recall bias.  Concentrations of serum 25(OH)D were not ascertained, 
making misclassification of vitamin D exposure likely, as it is difficult to discern 
if a mother’s report on her infant’s intake are correlated with increases in serum 
25(OH)D levels.  Further, the intake of cod liver oil, which contains vitamin A, 
was grouped with the vitamin D intake group although vitamin A can potentially 
attenuate the effect of vitamin D.   
 
In a multi-site U.S. analysis, Eckhardt et al.105 found that infants born to 
mothers with serum 25(OH)D levels ≥12 ng/mL during gestation (≤26 weeks 
gestation) had higher LAZ and head circumference z score (HCZ) measures 
across the first year of life compared with those born to mothers with levels 
<12 ng/ml yet the infants had similar WAZ scores. The finding that infants with 
lower vitamin D status are born with lower LAZ scores - and never catch up to 




(<12 ng/ml), even in developed countries such as the U.S., may cause 
differences in growth trajectories in infants across the first year of life.  A major 
assumption of this study however is that maternal vitamin D status is 
representative of the vitamin D status of infants throughout their first year of 
life. Nevertheless, this was a large cohort study (n=2473 mother-child pairs) 
and one of few to examine the effect of vitamin D status on changes in LAZ 
and HAZ prospectively, thus making it an important contribution to the field.   
 
A much older study, conducted in the 1930s, supplemented 12 infants with 
varying doses and followed them closely to measure their growth curves106. 
Some children experienced accelerated growth with vitamin D 
supplementation compared with the growth curves of standard reference 
population, while others experienced slower growth.  Yet it is difficult to make 
comparisons; a few subjects had higher than average growth trajectories from 
early infancy that are likely not due to vitamin D, and there was no control 
group. The authors concluded that a beneficial role of low doses of vitamin D 
on linear growth was found.  
 
The only RCT to supplement infants directly  (<1 year), rather than maternal 
supplementation during gestation, was conducted in India among low birth 




1400 IU of vitamin D3 given to infants aged 7 days – 6 months showed 
significant increases in WAZ scores (MD: 0.12; 95% CI: 0.01, 0.22, p=0.026); 
LAZ scores (MD: 0.12; 95% CIL 0.02, 0.21, p=0.014); and arm circumference 
(MD: 0.11, 95% CI: 0.01, 0.21, p=0.033) at 6 months of age, compared with 
infants given placebo. This indicates that increasing vitamin D status by direct 
supplementation of children, in a country that has a high prevalence of growth 
faltering, can have a positive impact on anthropometric parameters associated 
with undernutrition. Therefore, vitamin D status, without supplementation, can 
potentially influence growth as is studied in this dissertation. A follow-up to this 
study was conducted to measure if the modest gains noted during 
supplementation in infancy were maintained later in childhood. No differences 
in the sub-sample of children at age 3 to 6 years were found in the 
anthropometric measurements in terms of HAZ or WAZ in those who were 
supplemented during infancy versus those who were not. Although this 
indicates that there are no long term effects of early supplementation, there 
were no serum 25(OH)D measurements performed to ascertain 25(OH)D 
levels years after supplementation.   
 
A recent RCT, conducted in neighboring Bangladesh by Roth et al., 
supplemented mothers with a bolus dose of 35,000 IU/ week during the third 




their offspring at birth and at 1, 2, 4, 6 and 12 months108. The study found no 
significant differences in anthropometrics measured in the first 6 months of the 
infants’ life. They did however report that LAZ scores at 12 months were 
greater (mean ± SD: -0.89 ± 1.2) in infants of mothers supplemented with 
vitamin D compared with infants of mothers who were not supplemented (mean 
± SD: -1.33 ± 1.2) (MD: 0.44, 95% CI: 0.06, 0.82). The effect of vitamin D on 
LAZ resulted in a mean sex-adjusted increase of 1.1 cm in length (95% CI: 
0.06, 2.04; p=0.04) by 1 year. An even higher mean increase was observed 
when limiting the analysis to full term infants (sex adjusted increase of 1.5 cm; 
95% CI: 0.43, 2.57, p=0.006).  Roth et al. further found a lower proportion of 
stunting at 1 year in the supplemented group than in the placebo group (17% 
vs. 31%, p=0.049).  This is a significant contribution to understanding the effect 
of vitamin D status on post-natal growth. The results show that vitamin D status 
in infants has a positive effect on LAZ. An older RCT among first-generation 
Asian immigrants in the United Kingdom (UK)109 also supports the longer term 
benefit of growth from maternal vitamin D supplementation. They found a 
similar trend whereby infants born to mothers supplemented with 1000 IU/d 
during the third trimester were significantly longer at 9 and 12 months than 
those who were not supplemented, despite no differences in terms of birth 





Taken together, these results suggest that vitamin D can be a potentially 
modifiable risk factor to reduce stunting or improve growth in older infants. 
However, because of the limited number of studies, further research is needed, 
especially since a long gap between vitamin D supplementation and measures 
of growth outcomes are common in these studies. In addition to 
supplementation trials, further studies need to establish if vitamin D status at 
the time of anthropometric measurements is associated with growth. The 
current work examines the association between vitamin D status and stunting 
in a cross-sectional analysis, allowing for a better understanding of the 
potential association of 25(OH)D concentrations at the time of anthropometric 
measurements.  
 
A SPARSE EVIDENCE BASE TO DETERMINE THE ROLE OF VITAMIN D 
ON GROWTH IN EARLY CHILDHOOD AND PRE-ADOLESCENTS 
 
Data on vitamin D and growth are very limited in young children (>1 to 5 years) 
(Table 1-3). A 2009 systematic review by the Agency for Healthcare Research 
and Quality (AHRQ)110 commissioned by the United States and Canadian 
federal government agencies reported on the lack of studies in the 3 to 8 year 
life stage110.  The studies they reviewed indicate that in addition to the gap in 
data for the 3 to 8 year life stages, there are also no studies in the >1 to 2 year 




one by Kumar et al.111 which examined the long term benefit of infant 
supplementation in children aged 3 to 6 years as previously discussed, and 
the second by Gillbert-Diamond et al.112 which focused primarily on adiposity.  
Gillbert-Diamond et al.112 did however report that girls with vitamin D deficiency 
(<20 ng/ml) had a slower rate of linear growth than girls who were sufficient 
(≥20 ng/ml) (change in height -0.6 cm/y among deficient girls, p=0.04). By 
contrast, they did not find a similar trend in boys (change in height 0.3 cm/y 
among deficient boys, p=0.34). The lack of epidemiologic evidence relating 
vitamin D status with growth in children >1 but < 5 years is surprising – not only 
because growth faltering peaks at 18 months but also because it is most likely 
to occur in children younger than 5 years of age113. This indicates a gap in 
knowledge that needs to be addressed given the potentially important public 
health implications of poor growth in children. 
 
In older children, a study in Finland114, that supplemented pre-pubertal children 
(aged 8 to 10 years) with 400 IU of vitamin D2 5 to 7 times weekly (n=24) or 
placebo (n=27) for 13 months. The study measured serum 25(OH)D 
concentrations in the two supplementation groups and found no difference in 
the height, weight, or bone mineral content (BMC) between the two groups, 
despite a significantly higher serum 25(O)D concentration in the supplemented 




controlled trial among adolescent Lebanese girls115 aged 10 to 17 years 
(n=179) reported that in premenarcheal girls randomized to receive weekly 
doses of 1,400 IU or 14,000 IU for one year, linear growth was greater in 
supplemented girls. Although this finding approached significance (p=0.07), 
this finding along with differences in the rates of linear growth between girls 
and boys observed by Gilbert-Diamond et al.112, suggest that there may be 
differences in the impact of vitamin D on growth between boys and girls.  
 
Additional studies in the pre-adolescent age group have focused on the effects 
of early vitamin D exposure in the gestational time period over long-term effects 
on growth.  In a large cohort study in England, Sayers et al.93 found that 9 year 
old children born to women who had greater exposure to UVB radiation in the 
last 98 days of pregnancy had significantly higher height, weight, BMC and 
lean body mass than those born to mothers with less UVB exposure. An 
additional study measured maternal 25(OH)D concentrations during 
pregnancy (n=160) and found no difference in weight and height, but did find 
that at 9 years, children born to mothers with higher vitamin D status had higher 
BMC and bone area116. On the other hand, a much larger study (n=4451) that 
measured maternal vitamin D intake through a food frequency questionnaire 
(FFQ) during pregnancy found no significant differences in the anthropometrics 




25(OH)D concentrations in mothers during pregnancy also found null findings 
in offspring growth parameters at age 9 years118. These results are very hard 
to interpret, however, since they link an exposure that occurred many years 
prior to the outcome.  
 
TOO FEW STUDIES IN EACH AGE GROUP TO DETERMINE A ROLE OF 
VITAMIN D ON BONE MINERAL DENSITY 
Studies that examined the relationship between serum 25(OH)D levels and 
bone mineralization in children found more promising findings. These studies 
often focus on infants and preadolescent or adolescent children. No studies 
were conducted in pre-school children after the age of 1 year101, likely due to 
the need to use dual energy x-ray absorptiometry (DXA) scan, which requires 
children to remain very still during the exam to minimize artificats101.  Among 
RCTs, the study by El-Hajj Fuleihan115 found that premenarcheal girls who 
were randomized to 1,400 IU or 14,000 IU for one year had significant 
increases in lean mass, bone area of the total hip, and bone mass compared 
to the placebo group.  Similar findings were reported in a supplementation trial 
among 212 adolescent girls (aged 11 to 12 years) in Finland119, which found 
that daily supplementation with 200 or 400 IU showed bone mineral 





A meta-analysis of 6 RCTs in children120 found no effect of vitamin D 
supplementation on bone mass. This finding, however, needs to be interpreted 
cautiously, since the studies varied widely in age groups (8 to 17 years), 
supplement dosing (133 IU/day121 to 14,000 IU/week)115, and supplementation 
with or without milk or calcium. Several factors limit the interpretability and 
comparability of the literature.  For starters, the measures for growth in children 
and how these results are presented differ between studies. In some cases, 
measures of growth are reported in terms of growth velocity, changes in linear 
height, or HAZ, while others measure growth by changes in bone mass, using 
markers such as bone mineral density (BMD) or BMC. In the latter studies, 
reports of skeletal sites also differ substantially between studies; at times, 
findings differ even within various skeletal sites in the same population101.  
 
A second layer of complexity is that the age of participants in pediatric studies 
varies widely. Studies measuring infant anthropometric measurements often 
used maternal vitamin D status or supplementation during gestation to 
estimate the vitamin D status of young infants (<1 year). Many of the reported 
observational studies used a baseline 25(OH)D measurement to estimate the 
effect of vitamin D on growth months, and sometimes, years later. 
Supplementation trials are also difficult to interpret because serum 25(OH)D 




greatly. Finally, a major challenge - ubiquitous in the vitamin D literature - is 
that cutoffs used to compare vitamin D groups vary considerably, making it 








Table 1-3: List of pediatric studies examining the role of vitamin D on growth in children aged >1 year to pre-
adolescents  
 
Author, year Country N Age Sex Type of study 





US 6 – low 
vitamin D 
9 – high 
vitamin D 
<1 y Both Supplementation 
Low vitamin D 
- 3: 135 IU/d 
-3: 340 IU/d 
High vitamin D 
-2: 1800 IU/d vitamin D + 
6300 IU/d vitamin A 
-3: 2200 IU/d Vitamin D + 
1400 vitamin A 
4 infants: 4500 IU/d vitamin D 
1. Rate of growth with very high 
vitamin D similar or less than those of 
infants given 135 IU/d and lower than 
infants given 340 IU/d of vitamin D 
2. Authors conclude that vitamin D 
increases linear growth at intakes 
>135 IU/d but <1800 IU/d  















-1000 IU/d D2 given to 
mothers at 3rd trimester 
1. NS diff in length at birth, 3 mo, 6 mo. 
Sig. 9 mo  (p<0.05) and 12 mo 
(<0.001) 
 2. NS in BW. Sup. mothers had 
offspring with  sig. higher wt at 3, 6, 9, 
12 mo 
3. NS diff in head circumference at any 
time 
Ala-Houhala 






8-10 y Both RCT 
-Placebo 
-400 IU of D2, 5- 7/ wk 
1. NS effect on wt, ht or BMC of radius 








Author, year Country N Age  Sex Type of study  
(RCT vs, Obs) 
Key findings 





M + Ca2+ + 
D 
(n=240) 
M +  Ca2+ 
(n=207) 
10 -12 y F RCT ( 3 school randomization) 
2 year FU period 
-Control (no milk at school) 
-330 mL/milk with  Ca2+/wk 
-330 mL milk with 200-320 IU 
D3/wk 
1. Sig. increase in ht in those sup. with 
Milk + Ca2+ and Milk + Ca2++ D  
(p=0.001 and p<0.0005, respectively) 
2. M + Ca2+ + D group had greater 
increases in total BMC compared to 
control (p<0.0005) and M + Ca2+ grp 
(p=0.0006) 
Tobias et al. 
2005117 
UK 4451 9 y Both Cohort 
-measured anthro. of offspring 
at 9 y 
1. Maternal vitamin D intake during 
gestation (from FFQ).  
2. NS association with vitamin D intake 
of mother and ht, wt, total or spinal 
BMD or BMC in children 9 y 
Javaid et al. 
2006116 
UK 198 9 y Both Cohort 1. Reduced 25(OH)D vitamin 
D in mothers during late pregnancy 
associated with reduced whole-body 
(r=0.21, p=0.0088) and lumbar-spine 
(r=0.17, p=0.03) bone 
mass (p=0.0267) in children at age 9 y 
Stein et al. 
2006122 
US 168 4-8 y F Cross-sectional 
Vitamin D continuous variable 
1. 25(OH)2D negatively correlated 
with forearm bone mineral content  








Author, year Country N Age  Sex Type of study  
(RCT vs, Obs) 
Key findings 
Viljakainen 




200 IU D 
(n=65) 
400 IU D 
(n=74) 
11-12 y F RCT 
-Placebo 
-200 IU D3 
-400 IU D3 
1. NS effect of suppl. on ht (p=0.866), 
wt (p=0.055), or change in femur 
BMC (p=0.770) 













Both Prospective study 1. NS difference in length or wt at 
birth, 9 mo or 9 y in children of 
mothers with ≤12 ng/mL vs. those 




England 6995 9 y Both Cohort 
-UVB exposure during 3rd 
trimester.  
-Measured anthro. of 
offspring  at 9 y 
1. Sig. ht, wt, lean mass, BMC 
increases with increasing maternal 
UVB exposure in children at 9 y. Ht 
(p=0.017); wt (p=0.005); lean mass 
(p=0.00002);BMC (p=0.00001).  







5-12 y Both Prospective 
< 20 ng/mL 
≥20 - <30 ng/mL 
≥30 ng/mL 
1. Vitamin D deficient girls (<20 
ng/ml) had slower rate of growth 
(change in ht -0.6 cm/y p=0.04) 
in<20 ng/ml vs. ≥ 30 ng/ml  
2. NS difference in boys in <20 
ng/ml vs. ≥30 ng/ml  (change of ht 









Author, year Country N Age  Sex Type of study  




Netherlands 3750 Birth Both Cohort 




1. Women with <12 ng/ml 25(OH)D 
during pregnancy had infants with 
Sig. lower BW (MD:-114.4 g; 95% 
CI:-151.2,-77.6) and greater risk of 
SGA (OR:2.4;95% CI: 1.9, 3.2) 
Hyppönen et 
al. 2011104 









-Irregular suppl.:  <2000 
IU/d 
-Regular suppl.: ≥2000 IU/d 
1. Mothers reported suppl. of child 
2. Ht NS different in suppl. grp vs. 
non-suppl. at 1 y (p=0.34) or 14 y 
(p=0.26). 
Kumar et al. 
2011107 





-1400 IU D3/wk 
1. Suppl. low BW infants had greater 
HAZ, WAZ vs. placebo grp at 6 mo 
2. Mean WAZ D grp: -1.51 ±0.98 vs. 
WAZ placebo: -1.95 ± 0.99 (p=0.026) 
3. Mean HAZ D grp: -1.84 ± 0.98 vs. 
HAZ placebo: -1.95 ± 0.99 (p=0.014) 












-35,000 IU/wk  
During 3rd trimester of 
pregnancy 
1. NS difference in LAZ at birth 
between grps 
2. Sig. higher LAZ at 1 y in infants 
born to suppl. mothers vs. placebo 
(1.1 cm increase; 95% CI: 0.06, 2.0) 
3. Stunting less common in infants of 
suppl. mothers (17% stunted) vs. 







Author, year Country N Age Sex Type of study 
(RCT vs, Obs) 
Key findings 



















Maternal 25(OH)D : 
≥12 ng/ml 
<12 ng/ml 
1. Sig. higher LAZ and HCZ scores 
across first y of life in infants of 
mothers ≥12 ng/ml vs. those with 
<12 ng/ml 
2. WAZ and BMIZ NS at 1 y in two 
grps 
Hashemipour 
et al. 2014102 
Iran 130 Birth Both RCT 
Maternal suppl. 
Control grp: 200mg Ca2+ + 
400IU D3 
Suppl. grp: 
200 mg Ca2+ +50000 IU D3  
1. Sig. difference in BW (p=0.01) 
birth length (p=0.001), 
2. Head circumference (p=0.001) 
Abbreviation KEY: Suppl. (Supplementation); NS (Not significant); Sig. (significant); Grp (groups); Ht (height); Wt 
(weight); Anthro (anthropometrics); BW (birth weight); LAZ/HAZ (length/height for age z score); WAZ (weight for age z 
score); HCZ (height for age z score); BMC (bone mineral content); BMD (bone mineral density); FU (Follow-up); mo 






The evidence base for the effect of vitamin D status or vitamin D 
supplementation on growth is limited and even more so among 
undernourished children and children without clinical signs of rickets.  This is 
surprising given the major health implications related to growth faltering and 
stunting.  The improvements in LAZ scores with vitamin D supplementation in 
two trials107,108 conducted in LMIC countries suggest that vitamin D 
supplementation may be useful in treating stunting. A stronger evidence base 
to support the role of vitamin D on growth is required and will provide a better 
understanding if vitamin D can be used as an intervention to reduce the burden 
of stunting in children.  Further research, especially high quality RCTs, ideally 
conducted among different age groups and in different resource settings, will 
help to clarify the role that vitamin D plays on gains in height, weight, HAZ, and 
WAZ, BMC, and BMD among young children.  
PART III: VITAMIN D AND PNEUMONIA  
 
Childhood pneumonia is the leading cause of death in children less than 5 
years 123–128. Nearly 1.3 million (19%) deaths per year are attributable to 
pneumonia in children younger than 5 years123,128, with an estimated 99% of 
these deaths occurring in LMIC123.  Through efforts of the global community to 
reduce child mortality in the context of the MDG 4 goals, the incidence of 




and 2010. However, it is estimated that ~120 million episodes of pneumonia 
occurred in 2010, 14 million of which progressed to severe pneumonia128.  
 
In Ecuador, data from ENSANUT75 showed that the prevalence of pneumonia 
and severe pneumonia from July 2007 to June 2012 was 8.3% and 7.5% 
respectively (Figure 1-7). The prevalence differs by various ethnic groups (not 
shown in figure) and geographical location with the highest prevalence found 
in rural regions. In Quito, the prevalence is one of the lowest in the country for 
severe pneumonia (2.3%) and pneumonia (5.7%).  
 
Figure 1-7: Prevalence of pneumonia and severe pneumonia in Ecuador 
at the national level, by geographical area (urban vs. rural), and sub-
region according to data obtained from ENSANUT-Ecuador 201275 (data 
from 2007-2012). 
  




The most common type of pneumonia, community-acquired pneumonia (CAP), 
can be caused by both bacterial and viral pathogens129. The current estimates 
of the most common etiological agents of incident episodes of pneumonia, 
based on 2011 data developed by the Child Health Epidemiological Reference 
Group (CHERG) in collaboration with the World Health Organization (WHO) 
and UNICEF, are respiratory syncytial virus (RSV), influenza virus, 
Streptococcus pneumoniae (S. pneumoniae), and Haemophilus influenza b 
(Hib)123. RSV infections are also major contributors to severe pneumonia 
(22.6%), followed by S. pneumoniae (18.3%), influenza (7.0%), and Hib 
(4.1%). In Ecuador, the most common cause of incident pneumonia and severe 
pneumonia follows global evidence with RSV being the primary pathogen123.  
There is no vaccine available for RSV. However, some of the main contributors 
of severe pneumonia, such as S. pneumoniae and Hib, are vaccine 
preventable128.   
 
NUTRITIONAL RISK FACTORS OF PNEUMONIA INCIDENCE AND 
MORTALITY 
Undernutrition has been shown to be a major risk factor for pneumonia 
mortality72,128.  Children who are severely underweight (WAZ <-3), stunted 
(HAZ <-3) and wasted (WHZ <-3) are at an increased risk of mortality due to 
pneumonia [(OR: 6.4; 95% CI: 3.9, 10.4),  (OR: 3.2; 95% CI: 1.4, 6.7) and (OR: 




not breastfed or partially breastfed are at risk of pneumonia mortality (OR: 15.0; 
95% CI: 0.7, 332.7) and (OR: 2.5; 95% CI: 1.0, 6.0)], respectively. Crowding 
and indoor air pollution are important risk factors for pneumonia128. Zinc 
deficiency has also been shown to be a risk factor for pneumonia in the 
elderly130,131. Elderly subjects who had higher serum zinc concentrations (≥70 
µg/dL) had a lower incidence of pneumonia and a shorter duration of 
pneumonia illness compared to those with a lower zinc serum concentrations 
(<70 µg/dL) [RR: 0.52; 95% CI: 0.36, 0.76) and (MD: -3.9; 955 CI: -6.2, -1.6), 
respectively]131.  
 
 It is estimated that scaling up interventions would result in 67% fewer deaths 
from pneumonia in young children by 5 years by 2025 at cost of $6.715 
billion71.  Simple measures, such as improved hand washing practices, 
reduction in indoor air pollution132 and zinc supplementation133 have been 
shown to be cost effective at preventing pneumonia134. 
 
CHILDREN WITH RICKETS ARE MORE LIKELY TO BE HOSPITALIZED 
WITH PNEUMONIA  
The earliest epidemiological studies which showed a possible association 
between vitamin D deficiency and pneumonia were amongst children with 
nutritional rickets. In 19754, Salimpour noted that 200 rachitic children in 




conducted by Najada et al.136 compared 2 month to 2 year old children 
diagnosed with nutritional rickets with non-rachitic children who were 
hospitalized and found that 40 of the 47 (85.1%) hospitalized rachitic children 
were admitted to the hospital for lower respiratory tract infection (LRTI). 
Further, rachitic children had a significantly longer duration of hospitalization 
than non-rachitic children (9.5 days vs. 7.4 days, p=0.002).  A case control 
study in Ethiopia137 compared children hospitalized for pneumonia to those not 
hospitalized for pneumonia and found that pneumonia cases were more likely 
to be diagnosed with rickets compared to controls. This association was 
maintained even after adjusting for common risk factors for both pneumonia 
and rickets such as underweight, stunting, family size, and birth order (ORadj: 
22.11; 95% CI: 11.34, 43.12, p<0.0001).  
 
These studies provide empirical evidence that rickets is a risk factor for 
pneumonia. These studies have not shown whether vitamin D deficiency in 
children without rickets places children at higher risk of pneumonia.   
 
PNEUMONIA IN CHILDREN WITHOUT RICKETS 
 
Several observational studies have provided evidence that vitamin D 
deficiency, in the absence of rickets, is associated with hospitalization with 
pneumonia.  A hospital case-control study in India138 showed that children ≤5 




mean serum 25(OH)D concentration >22.5 ng/ml compared  to healthy 
controls (n=70) who attended the hospital during the study for routine 
vaccination (OR: 0.09; 95% CI:0.03, 0.24, p<0.001).  A matched case-control 
study (n=25 pairs) in north-eastern Bangladesh found that children aged 1 to 
18 months hospitalized with pneumonia had significantly lower mean 25(OH)D 
concentrations than controls matched on age, sex, and village (11.6 ng/ml vs. 
15.6 ng/ml; p=0.015)139. These two case-control studies suggest that vitamin 
D deficiency may put children at a greater risk of developing ALRI requiring 
hospitalization compared to a healthy population.  
 
On the other hand, in a well powered case-control study amongst Canadian 
children aged 1-25 months, cases hospitalized for uncomplicated ALRI (n=64) 
and controls undergoing elective surgery at the same hospital (n=65) reported 
no significant differences with vitamin D status among cases and controls using 
two vitamin D thresholds (<16 ng/ml (<40 nmol/L): 4.7% vs. 1.5%, p=0.365; 
<32 ng/ml (<80 nmol/L): 51.6% vs. 56.9%, p=0.598)108. The serum 25(OH)D 
concentrations were similar for cases and controls (30.8 ± 8.2 vs. 30.9 ± 9.7 
ng/ml, p=0.96).  Children in this study had much higher mean levels of 
25(OH)D than in the two studies conducted in India and Bangladesh and may 
be the reason why no difference was found between the cases and controls. 
This study however is less important in understanding if vitamin D status is 




controls that are at the hospital for a reason other than pneumonia.  A more 
important study performed by McNally et al. a few years later was a hospital 
case control study in Canada. McNally et al.140 which found similar findings to 
the previous Canadian study in terms of the mean 25(OH)D levels being similar 
between cases (n=105) admitted for ALRI and controls (n=92) (cases: 32.4 ± 
16.0 ng/ml vs. 33.2 ± 12.0 ng/ml; p=0.71).  They did however find significantly 
lower mean 25(OH)D levels in the ALRI cases admitted to the pediatric 
intensive care unit (PICU) than those cases admitted to the general pediatric 
ward (PICU: 19.6 ± 9.6; general ward: 34.8 ± 15.6 ng/ml, p=0.001) and a higher 
proportion of children with <20 ng/ml serum concentrations (50% vs. 20%, 
p=0.02 respectively). In this analysis, McNally et al. are comparing the severity 
of disease by vitamin D status among children that are hospitalized with 
pneumonia.  
 
These findings indicate that vitamin D status is associated with severity of ALRI 
and suggest that children with lower vitamin D status may be susceptible to 
more severe forms of pneumonia which could potentially cause a longer 
duration of illness. Of all the case-control studies, the McNally et al.140 study is 
most similar to the question asked in this dissertation. The reason being is that 
aside from the case-control analysis, the study compares vitamin D status 
among children hospitalized with ALRI and measures the consequences of 




McNally et al. study offers the most supportive evidence of the case-control 
studies described, i.e. that vitamin D status is in fact associated with greater 
severity of illness and thus may potentially impact duration of illness due to 
pneumonia. The current work will be slightly different since vitamin D status in 
children hospitalized with pneumonia is examined to determine if there are 
differences in the duration of illness of pneumonia, rather than PICU admission 
(a proxy for severity of infection).   
 
One possible explanation for the divergent findings between the Canadian 
studies and those conducted in India and Bangladesh may be due to different 
underlying etiology of ALRI139. In the Canadian study by Roth et al.108, the 
majority of cases of ALRI had bronchiolitis (60/64, 93.8%) while only (4/64, 
6.2%) had a pneumonia diagnosis. Also, in the study by McNally et al.140, a 
sub-group analysis which compared cases and controls diagnosed with 
bronchiolitis and cases and controls diagnosed with pneumonia showed that a 
significant proportion of children with pneumonia were vitamin D deficient (<20 
ng/ml) compared to controls (30% vs. 16%; p=0.07). However, cases with 
bronchiolitis did not have a greater proportion of deficiency (<20 ng/ml) 
compared to controls (19% vs. 16%; p=0.61). The pathogen etiology in the 
Southeast Asian studies was not determined. This suggests that vitamin D 
status may be associated with differences in the underlying etiology of 




differences in response to supplementation as well as intervention strategies. 
The current work investigates whether there are differences in the underlying 
etiology of pneumonia by vitamin D status to address this question.  
 
VITAMIN D SUPPLEMENTATION IS NOT ASSOCIATED WITH SHORTER 
DURATION OF PNEUMONIA ILLNESS 
Given that there have been studies that found that vitamin D status is 
associated with pneumonia, a natural next step was to investigate if vitamin D 
supplementation was associated with decreased time to remission of illness. 
A randomized placebo controlled trial conducted in India which randomized 
children 2 to 12 months to 1000 IU/day for 5 days (n=100) and children >12 
months to 5 years with 2000 IU/day for 5 days (n=100) and placebo (n=100) 
was conducted among children hospitalized for pneumonia141. They found no 
difference in the median time to resolution of severe pneumonia between the 
vitamin D supplemented children and the placebo group (median (SE, 95% 
CI): vitamin D group: 72 hours (3.7, 64.7 - 79.3 hours); placebo: 64 hours (4.5, 
55.2 - 72.8 hours). 
 
The same group, which conducted the RCT to determine incidence of 
pneumonia with vitamin D supplementation in Afghanistan142, also conducted 
a placebo-controlled RCT among children (aged 1 to 36 months) hospitalized 




supplementation reduced the risk of repeat episodes143. They supplemented 
children with a bolus dose (100,000 IU) of vitamin D3. No significant difference 
in the duration of illness was observed between the supplemented (n=224) and 
placebo (n=229) (p=0.17) groups; however, children supplemented with 
vitamin D were less likely to experience a repeat episode of CAP (HR: 0.71; 
95% CI: 0.53, 0.95).  
 
Although these studies did not find an association between vitamin D 
supplementation and duration of illness, it is important to consider that the 
duration of supplementation was relatively short during these studies and 
therefore there may not be enough time to discern a beneficial role of vitamin 
D as an adjunct to therapy. Also, these are the only two studies which 
examined the effect of supplementation with vitamin D on pneumonia illness 
duration in children. More studies are required to make conclusions. The 
current research looks at the same outcomes of duration of pneumonia illness, 
and although this is not an RCT, it will offer further insight on whether vitamin 
D status is associated with duration of pneumonia illness.    
 
Vitamin D and Incidence of pneumonia and other RTIs 
Beyond the scope of looking at vitamin D as a risk factor for pneumonia 
duration, many studies have examined if vitamin D can be used to prevent 




and children and found an overall protective effect of vitamin D 
supplementation and incident RTI (OR: 0.64; 95% CI: 0.49, 0.84).  A 2015 
meta-analysis limited to the pediatric population (<18 years) identified 7 RCTs 
and found no reduction in the risk of RTI (RR: 0.79; 95% CI: 0.55, 1.13) or 
hospital admission due to respiratory infection (RR: 0.95; 95% CI: 0.72, 
1.26)145.  The largest RCT conducted in a pediatric population, by Manaseki-
Holland and colleagues142 (n=3046), reported that infants aged 1 to 11 months 
in Afghanistan randomized to receive a quarterly dose of vitamin D3 (100,000 
IU) (n=1524) or placebo (n=1522) for 18 months had no effect on the first 
incidence of CAP compared to the placebo group (IRR: 1.06; 95% CI: 0.89, 
1.27).  
 
Genetic factors that may affect susceptibility to CAP 
VDR polymorphism may play a significant role in the risk for CAP. A case-
control study among Chinese Han population found that children with the 
rs2239185 VDR gene with the TT allele had a higher risk of CAP than those 
with the CC + CT genotypes (p=0.008).  Also, the TT allele was more likely to 
be present among cases of CAP (11/91) than healthy controls (2/94) (OR: 7.15; 
95% CI: 1.5, 34.0, p=0.045).   
 
A systemic review and meta-analysis53 of 3 case-control studies investigating 




children found that the Fokl (rs2228570) minor allele was significantly 
associated with severe RSV bronchiolitis requiring hospitalization in children 
(OR: 1.52: 95% CI: 1.12, 2.05). Twos studies included in the meta-analysis 
found no association with the TaqI (rs731236) allele and risk of hospitalization 
with RSV.  This may be a risk factor for increased severity of RSV and therefore 
is worth considering as a potential reason for differences in illness duration and 
susceptibility to RSV.  
 
PART IV: VITAMIN D STATUS IN LATIN AMERICA  
Having discussed the background of vitamin D, it is necessary to turn the focus 
of the discussion and place vitamin D in the context of the study population 
that encompasses the research set forth in this dissertation.  
 
Most vitamin D studies have focused on North America, Europe and 
Oceania66. In Latin America, the number of publications is lower than many 
regions of the world and thus the prevalence of vitamin D status is not well 
established, especially in children146. There are reports of the prevalence of 
vitamin D deficiency published in Argentina147,148, Brazil149, Chile146, 
Colombia112,150, Costa Rica151, Ecuador22,152, Guatemala153 and Mexico154. 
Many of these are in adults and the elderly146.  Reports of dietary intake of 




Ecuador22 show that the diets in these regions are lower than the current 
recommendations set forth by the IOM.  
 
There has been one study conducted in pre-adolescent children and no studies 
conducted amongst young children <5 years112 in Andean countries.  In 
Bogota, Colombia, the prevalence of deficiency (<20 ng/ml) was 12% and that 
of insufficiency (20-29 ng/ml) was 51% in pre-adolescent girls (5 - 12 years)150 
(Figure 1-9).   
 
A recent study among elderly Ecuadorians152, using data from the National 
Survey of Health, Wellbeing and Aging, found a high level of vitamin D 
deficiency (<20 ng/ml) (21.6% (95% CI: 19.5, 23.7)) and insufficiency (<30 
ng/ml) (67.8% (95% CI: 65.3, 70.2)) despite the abundant sunlight available. 
This is higher than rates reported previously among the elderly in Ecuador 
which found that 19% of women and 9% of men were deficient (<20 ng/ml)155. 
Another study among elderly Mayans of Guatemala reported a 46% 
prevalence of vitamin D deficiency (<20 ng/ml)153.   
 
A considerable prevalence of vitamin D insufficiency and deficiency in different 
age groups in children has been reported despite environmental factors that 
favor vitamin D production. Deficiency (<20 ng/mL) in the pediatric Latin 




ranged from 9.4% to 46.4% (Figure 1-9).  Of the studies conducted in Latin 
American children (Figure 1-9), the data from Mexico154 come from a nationally 
representative data set, one study in the Patagonia region of Argentina147 and 
another in Bogota, Colombia112 are representative of these respective regions, 


































Figure 1-9: Vitamin D status among Latin American children1 
 
 
Adapted from Brito A, Cori H, Olivares M, et al. Less than adequate vitamin D status 
and intake in Latin America and the Caribbean: A problem of unknown magnitude. 
Food & Nutrition Bulletin; 2013;34: 52–64146.  
 
1Footnote: Ushuaia, Argentina: Oliveri et al. 1983148; Costa Rica: Brehm et al. 2009151; 
Patagonia, Argentina: Durán et al. 2009147; Bogota, Colombia: Gilbert-Diamond et al. 
2010112; Paraná, Brazil: Santos et al. 2012149; Mexico (nationally representative): Flores et al. 
2013154;  Puerto Rico: Suárez- Martínez et al. 2013156; Peru (peri-urban towns Lima and rural 





PART V: GOALS OF THE DISSERTATION 
Although the Andean capitol of Quito resides in equatorial latitude and high 
altitude, there is little data on the vitamin D status of children in the Ecuadorian 
Andes. Many studies, which have assumed that participants would have adequate 
vitamin D status, have in fact found a higher prevalence of vitamin D deficiency 
than expected. There is a need to determine the vitamin D status in an Andean 
population in young children, as vitamin D deficiency is associated with rickets, 
infectious diseases, autoimmune diseases, critical illness and obesity. This would 
be the first study to determine vitamin D status in the pediatric Ecuadorian 
population as well as the first study to look at the vitamin D status among Andean 
children <5 years. 
 
More importantly, in this research I explored whether children who were 
underweight were more likely to have lower 25(OH)D and also whether a lower 
concentration of serum 25(OH)D was associated with stunting.  Vitamin D 
deficiency is one of the primary causes of rickets and a primary manifestation of 
this disease is stunting. Could it then be possible that vitamin D is associated with 
stunting, a far more prevalent disorder than rickets, that impacts childhood 
mortality and morbidity? This would be the first study to look at vitamin D and 
stunting in children 6 to 36 months old who do not have rickets.  Further, being 
underweight may be a risk factor for low vitamin D status. However there are only 




This study will examine if children who are underweight are more likely to have low 
vitamin D status. 
 
This research also examines the association between vitamin D and immune 
function. The study examines if vitamin D status was associated with time to 
remission of severe pneumonia. Although there is significant research on the effect 
of vitamin D and pneumonia in children, the conflicting results in the literature keep 
this question still open. Finally, an analysis of baseline measurements of growth 
on prospective anthropometric measurements is presented in Appendix 2. 
 
The current research uses two cohort studies to examine the research questions 
set forth. A sub-analysis of two previously conducted randomized, double-blind, 
placebo-controlled trials will be carried out. The first, the Vitamin A and Zinc 
Prevention of Pneumonia (VAZPOP) trial, was a weight-stratified, community-
based trial involving children aged 6 to 36 months living in urban slums of Quito, 
Ecuador who were randomized to receive vitamin A (10,000 IU) and/or daily zinc 
supplementation (12.5 mg) and followed for 50 weeks to determine the impact on 
episodes of pneumonia and diarrheal disease, and growth. The second, the 
Ecuador Pneumonia and Zinc supplementation trial (EcuaPAZ) was a placebo-
controlled trial that evaluated the impact of short-course, high-dose zinc 
supplementation in children aged 2 to 59 months with severe pneumonia admitted 





OBJECTIVES OF THE DISSERTATION 
1. To measure the prevalence of vitamin D deficiency and insufficiency in a low 
socio-economic status (SES) weight-stratified sample of children 6 to 36 
months residing in the Ecuadorian Andes  
2. To determine the association between underweight, stunting and vitamin D 
status in children aged 6 to 36 months 
a. Determine if vitamin D status differs between underweight children 
and normal weight children 
b. Determine if children with lower levels of vitamin D are more likely to 
be stunted than those with higher levels 
3. To determine the association between vitamin D status and severe pneumonia 
in a hospital-based population (EcuaPAZ) in children aged 2 to 59 months 
a. Determine if vitamin D deficiency is associated with a longer time to 
remission of respiratory signs of pneumonia 
b. Determine if vitamin D status is associated with bacterial or viral 
etiology 
4. To determine if baseline vitamin D status is associated with changes in height-
for-age and weight-for-age z scores over a 50-week follow-up period in children 
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Background: Although a plethora of studies evaluating vitamin D status exist 
globally, there is a gap in knowledge on the vitamin D status of children residing in 
the Andes and its association with undernutrition. 
Objective:  The study objectives were to evaluate the vitamin D status of children 
residing in a low socio-economic status (SES) setting in the Ecuadorian Andes; 
and to assess the association between vitamin D status, stunting and underweight. 
We hypothesize that children who were underweight have lower serum 25(OH)D 
levels and that lower 25(OH)D levels would be associated with a higher risk of 
stunting. 
Design: We conducted a cross-sectional secondary analysis of a randomized 
controlled trial, the Vitamin A, Zinc and Pneumonia study. Children, aged 6-36 
months, residing in five low SES peri-urban neighborhoods near Quito, Ecuador 
had serum 25(OH)D concentrations measured. A sensitivity analysis was 
undertaken to determine a vitamin D cutoff specific for our endpoints. Associations 
between serum 25(OH)D and underweight (defined as weight-for-age z-scores ≤-
1 standard deviations [SD]) and stunting (defined as height-for-age z-scores ≤-2 
SD) were assessed using multivariate logistic regression.  
Results: The mean serum 25(OH)D concentration of the 516 subjects was 23.2 ± 
7.1 ng/ml. The sensitivity analysis revealed an undernutrition-specific cutoff of 
25(OH)D <17 ng/ml; 18.6% of children had serum 25(OH)D levels <17 ng/ml. 




ng/mL) and insufficiency (20 to <30 ng/mL), 35% of children were deficient and 
46.1% were insufficient. Children who were underweight were more likely to have 
serum 25(OH)D levels <17 ng/mL (adjusted odds ratio (OR): 2.0; 95% CI: 1.2, 3.3). 
Children with low serum 25(OH)D levels were more likely to be stunted (adjusted 
OR: 2.8; 95% CI: 1.6, 4.7).  
Conclusions: Low serum 25(OH)D levels were more common in underweight and 
stunted Ecuadorian children. 
 
Keywords: Vitamin D deficiency, 25(OH)D, ng/ml, nmol/L, children, z scores, 








Vitamin D deficiency has increasingly been reported in many regions of the world 
in both adults and children66,67,158–161. In comparison to North America and Europe, 
Latin America is a region where vitamin D research has been underrepresented, 
particularly in the pediatric population146,160,162. In young children (<5 years), data 
from the Patagonia region of Argentina147 (6 to 23 months) and Mexico (2 to 5 
years)154 show a prevalence of vitamin D deficiency (<20 ng/ml) of nearly 24%. 
However, there is limited knowledge of the prevalence of vitamin D status among 
young children living in the high altitude Andean countries. One study published in 
the Andean capital of Bogota, Colombia amongst pre-adolescent girls (5 to 12 
years) showed that 12% of girls were vitamin D deficient (<20 ng/ml) and 51% 
were insufficient (20 to 29 ng/ml)150.  
 
Since exposure of skin to solar ultraviolet B (UVB) radiation and cutaneous 
production is a major source of vitamin D, regions with low latitudes should 
theoretically have a low prevalence of vitamin D deficiency. With its equatorial 
latitude, the Ecuadorian capital Quito receives nearly 12 hours of sunlight year 
round, and has an altitude of 2,800 meters above sea level. Both conditions 
increase the solar ultraviolet radiation index27 and are conducive to epidermal 
vitamin D synthesis7. However, previous studies in countries with low 
latitude66,163,164 and/or high altitude112,153,165 show that this does not necessarily 




Vitamin D deficiency is of particular concern in growing children166,167. The 
Generation R study, a large multiethnic cohort of 6 year olds in the Netherlands, 
found that children who were underweight (defined by BMI z scores) had a higher 
risk of vitamin D deficiency (<20 ng/ml) compared to normal weight children168. 
Vitamin D status influences linear growth, even in children with no clinical signs of 
rickets. A study among South African children aged 2 to 5 years found that stunted 
children were less likely to consume vitamin D along with other key components 
of milk such as calcium, riboflavin and fat than non-stunted children169. In India, a 
randomized placebo-controlled trial with 2709 full term, low birth weight infants, 
found that infants randomized to a weekly dose of 1400 IU of vitamin D3 from 7 
days to six months of age had significant increases in length, weight, and mid-
upper arm circumference compared to infants given placebo 107. However, the 
anthropometric gains from the short term supplementation trial did not appear to 
be sustained when a sub-sample of these children had their anthropometries re-
measured at 3 to 6 years of age111. Each of these studies underlines the 
importance of vitamin D for normal growth of young children.  
 
Given the lack of information on the vitamin D status amongst Ecuadorian children 
and its potentially important effects on growth, we performed a secondary analysis 
using a convenience sample of children participating in a clinical trial in Ecuador. 
The objectives of this analysis were to measure the prevalence of vitamin D 




children 6 to 36 months residing in the Ecuadorian Andes; assess whether vitamin 
D status differs between underweight children and normal weight children; and 
determine whether children with lower levels of vitamin D were more likely to be 
stunted than those with higher levels.  
 
SUBJECTS AND METHODS 
Study setting 
This study was carried out in low SES peri-urban neighborhoods, called ‘barrios’, 
in Quito, Ecuador. The barrios are located on the hilly outskirts around 20 km 
northwest of downtown Quito with elevations greater than 2,800 m above sea level. 
The study was carried out in five neighborhoods: Atucucho, Caminos de la 
Libertad, Colinas del Norte, Pisuli, and Roldos. These impoverished barrios had 
poor infrastructure and limited healthcare facilities. In 2000, a baseline survey of 
the barrios showed that households had a mean monthly income of US$54, which 
was 50% below the mean basic income in Ecuador. Only 52% of households had 
a municipal source of potable water while 62% had sewer access. 
Study design 
This was a cross-sectional analysis of subjects who participated in a larger 
randomized control trial, the Vitamin A, Zinc and Pneumonia (VAZPOP) study 
(clinicaltrial.gov identifier number NCT00228254). During 2000-2003, children 




beginning in July. Individual participation lasted one year. To be enrolled in the 
trial, children had to be 6 to 36 months old, have had no recent micronutrient 
supplementation, and reside in one of the five study neighborhoods for at least one 
year. Study enrollment was weight-stratified, with approximately 200 - 220 children 
selected in each of the following weight-for-age z-score (WAZ) strata: underweight 
(WAZ ≤-2), mildly underweight (-1≤ WAZ >-2), and well nourished (WAZ >-1) 
based on the National Institute of Child Health and Human Development (NICHD) 
reference growth curves (Epi-Info 2002, Centers for Disease Control, Atlanta, 
Georgia, USA). The current cross sectional study was limited to subjects from the 
last year of VAZPOP who had a minimum of 100 µL of serum from their baseline 
blood draw. 
Anthropometric measurements 
Anthropometric measures were collected at baseline between June 12th-July 2nd 
2003. Trained study personnel performed height, length, and weight measures. 
Length was measured in children <24 months using horizontal scales. Standing 
height was measured for children ≥24 months using non-distensible plastic tape 
fixed onto a vertical board. Height and length were measured to the nearest 0.1 
cm. Weight was measured using Detecto® Health-o-meters balance scale (Webb 
City, Iowa, USA) to the nearest 0.1 kg. Anthropometric devices for weight and 
height measurements were calibrated yearly for accuracy by the National Bureau 
of Standards of Ecuador. Although the VAZPOP study used the NICHD reference 




scores (WHZ) were calculated using the 2007 WHO growth standards (WHO 
Anthro version 3.2.2, January 2011, WHO,  
http://www.who.int/childgrowth/software/en/) in this study. Children who had a HAZ 
score of ≤-2 standard deviations (SD) below the median of the WHO child growth 
standards were categorized as stunted. Children who had a WAZ score of ≤-1 SD 
below the median reference growth standards were categorized as underweight; 
this group included both mildly and significantly underweight children. We 
compared children with WAZ ≤-1 SD to those with WAZ >-1 SD in our models 
instead of WAZ ≤-2 SD since a stronger association between WAZ ≤-1 SD and 
vitamin D status was observed in initial analyses.  
Biochemical analysis 
Venous blood was collected at baseline from children in trace element free tubes 
(Sarstedt AG, Nümbrecht, Germany). The blood samples were transported to the 
laboratory in a cooler with ice packs to Pontificia Universidad Católica del Ecuador 
where they were stored in -80˚C freezers and subsequently shipped to Boston for 
vitamin D analyses.  
 
Hemoglobin was measured at baseline with a finger prick sample using the 
HemoCue Hb 201+ assay. Serum 25(OH)D and intact parathyroid hormone (iPTH) 
(amino acids 1-84) were measured at the Vitamin D Lab at the Boston University 




immunoassay developed by Immunodiagnostic Systems Inc. (IDS-iSYS; 
Immunodiagnostic systems Ltd, Boldon, UK) which uses an ester magnetic particle 
chemiluminescence immunoassay (CLIA) technique. The assay for 25(OH)D was 
validated at the Vitamin D Lab against high performance liquid chromatography 
with tandem mass spectrometry (LC/MS/MS), the gold standard for 25(OH)D 
determination, using additional control samples. A single determination of 
25(OH)D and iPTH was measured. However, of those that had >400 µL of serum, 
a 20% random sample was used to measure 25(OH)D in duplicate.  
 
The assay recognizes 25(OH)D3 and 25(OH)D2 equally well, with a dynamic range 
of 6 to 126 ng/ml. The lower limit of detection of the 25(OH)D assay was 6 ng/ml. 
Subjects below the detection limit of the assay were assigned a value of 6 ng/ml 
(n=2) for their 25(OH)D concentration. Subjects below the detection limit of the 
iPTH assay (<5 pg/ml) were assigned a value of 5 pg/ml (n = 9) with a dynamic 
range of 5 to 100 pg/ml.    
 
Control samples were inserted at periodic intervals for quality control purposes. 
The inter-class coefficients of variability (CV) for serum 25(OH)D at the high, 
medium, and low levels was 11.1%, 5.7% and 6.0%, respectively and for iPTH 
they were 7.4%, 4.1% and 5.0%. The intra-assay CV for the current analysis was 




Interpretation of vitamin D status 
Existing recommendations for interpreting vitamin D status focus on bone 
metabolism 19,23,56,57,170 and no guidance exists for linking serum levels to 
undernutrition. We conducted a sensitivity analysis to ascertain the 25(OH)D 
concentration that showed the strongest associations between 25(OH)D, HAZ and 
WAZ (Supplemental Table 2-1). For the sensitivity analysis, a series of univariate 
logistic regression models were carried out with 25(OH)D cutoffs changing from 
12 to 30 ng/ml in 1 ng/ml increments (e.g. 12, 13, 14 ng/ml, etc.). In these analyses, 
a cutoff value for serum 25(OH)D of 17 ng/ml was found to be most strongly 
associated with HAZ and WAZ and was therefore used in this study. For 
comparison to other studies, we also used the Institute of Medicine (IOM) 
definitions (at risk of classic vitamin D deficiency states such as rickets): <12 ng/ml 
(<30 nmol/L); risk of inadequacy: 12 to 19 ng/ml (30 to 49 nmol/L); sufficiency: ≥20 
ng/ml (≥50 nmol/L) 170 and Endocrine Society Practice Guidelines (deficiency: <20 
ng/ml (<50 nmol/L); insufficiency: 20 to 29 ng/ml (50 to <75 nmol/L); sufficiency: 
≥30 ng/ml (≥75 nmol/L) 19.   
Statistical Analyses 
Data analysis was performed using SAS Release 9.3® (SAS Institute Inc., Cary, 
NC). Results are presented as mean and SD for continuous variables, or as 
number and percentage for categorical variables. The mean difference and 95% 




examine the relationship between 25(OH)D concentrations (continuous) and PTH 
(continuous).  
 
Two analyses were performed. The first was to examine WAZ as a predictor of 
vitamin D status. We hypothesize that underweight children are at greater risk of 
lower serum 25(OH)D levels due to less dietary intake. The second analysis 
examined vitamin D status as a predictor of stunting since lower vitamin D levels 
may contribute to less than optimal bone growth.   
 
Multiple logistic regression analyses were performed to examine the relationship 
between underweight as measured by WAZ (independent variable) and vitamin D 
status (dependent variable) as well as between vitamin D status (independent 
variable) and stunting (dependent variable). To control for confounding, each 
potential confounder was added individually to the model. Variables that changed 
the main exposure effect estimate by more than 10% were included in the 
multivariate model. The following potential variables were considered for the 
model: height, weight, sex, age, SES variables, hemoglobin concentration, and 
iPTH. SES variables were available in a subset of children. These include maternal 
education and paternal education (illiterate, primary school, high school or higher 
education), access to sanitary facilities (household access to toilet vs. non-toilet 




to potable water), type of household construction (block construction vs. other type 
of construction (e.g. wooden), household ownership (own, rent, other), number of 
persons per household, number of rooms per household, and a crowding index 
(calculated as the number of persons per household/number of rooms per 
household). To avoid multicollinearity, a Spearman correlation was calculated for 
binary and ordinal data while a Pearson correlation was calculated for continuous 
variables. Variables that were highly correlated were not included in the same 
model. The most parsimonious model which controlled for all known confounders 
was chosen for our final multivariate models. 
Ethical review 
Parental informed consent was obtained for each child who participated in the 
study. The Boston University Institutional Review Board and the Ethical 





In total, 526 of the 645 children who participated in the final phase of VAZPOP had 
baseline serum 25(OH)D analyzed. The remaining 119 subjects were excluded 




subjects were also excluded for having missing measures of weight and/or height, 
leaving 516 for analysis.  
A similar number of males and females participated in the study (Table 2-1); their 
mean age was 17.9 ± 8.0 months with >70% of children being >12 months of age. 
Underweight and normal weight children had similar age distributions. There were 
no important differences in household characteristics between the underweight 
and normal weight groups. As expected for this WAZ stratified sample, 65.5% 
(337/516) were underweight (WAZ ≤-1 and WAZ ≤-2) and the rest were normal 
weight (WAZ >-1). About two thirds (62.2%, 321/516) of children were stunted 
(HAZ ≤-2), and 3.1% (16/516) were wasted (WHZ ≤-2). Children who were 
underweight were shorter (mean difference (MD): 3.4 cm; 95% CI: 1.9, 4.8 cm) 
and had lower mean HAZ scores (MD: 1.3 SD; 95% CI: 1.2, 1.5) than children who 
were normal weight. The mean WHZ scores also differed between the two WAZ 
categories (MD: 1.2 SD; 95% CI: 1.1, 1.3). 
 
We explored potential confounding by a wide range of SES-related variables 
(shown in Table 2-1). Since many subjects had missing SES variables, we 
compared the SES-adjusted models with the SES-unadjusted models in the subset 
of subjects with non-missing data and the effect estimates were virtually identical. 
Therefore we removed all SES variables from the final models. There was also no 




variables did not differ significantly from those subjects that did not have SES 
variables (Supplemental Table 2-2). This result is consistent with the objectives 
of the parent VAZPOP study, which sought to minimize SES effects by conducting 
the study in poor neighborhoods.  
Distribution of serum 25(OH)D concentrations among children 
Figure 1 shows the distribution of serum 25(OH)D among study participants. The 
mean ± SD serum 25(OH)D concentration was 23.2 ± 7.1 ng/ml. Using our study 
specific cutoff, 18.6% of children had a serum 25(OH)D level of <17 ng/ml (Table 
2-2). According to the IOM cutoffs23, only 3.5% of children were at risk of deficiency 
(<12 ng/ml) and 31.6% were at risk of inadequacy (12 to 19 ng/ml). Using the 
Endocrine Society Practice Guidelines definitions19, 35.1% were deficient (<20 
ng/ml) and 44.4% were insufficient (20 to 29 ng/mL). Overall, the mean 25(OH)D 
concentration was similar in children who were underweight and normal weight 
(MD: 0.16 ng/ml; 95% CI: -1.1, 1.4), although the likelihood of being classified with 
25(OH)D levels <17 ng/ml was higher in underweight than normal weight children 
(22.0% vs. 12.3%, respectively) (Table 2-1). This is because the distribution of 
serum 25(OH)D differed between the two weight groups (Figure 2-2). Children 
who were stunted had mean serum 25(OH)D concentrations of 22.7 ± 7.4 ng/ml 
and those that were not stunted had a mean level of 24.0 ± 6.4 ng/ml (MD: 1.3 
ng/ml; 95% CI: 0.13, 2.6). Mean 25(OH)D serum concentrations were highest in 6 
to 12 months infants compared to older children (>12 months) (MD: 4.0 ng/ml; 95% 




Serum 25(OH)D and PTH  
Intact PTH was measured in the subjects (n = 396) who had sufficient serum to 
allow both 25(OH)D and PTH assessment. The mean PTH was similar in the two 
vitamin D status categories (Table 2-3) (MD: 1.6 pg/ml; 95% CI: -2.0, 5.2). 
Similarly, there was no difference in the mean PTH amongst children who were 
normal weight versus underweight (MD: -0.12 pg/ml; 95% CI: -3.1, 2.8). The linear 
regression analysis showed an inverse relationship between 25(OH)D and PTH, 
although this was not statistically significant (β=-0.20, p=0.062). 
Weight and vitamin D status  
Underweight children were twice as likely to have serum 25(OH)D levels <17 ng/ml 
compared to children who were normal weight (unadjusted OR: 2.0; 95% CI: 1.2, 
3.4) (Table 2-3). After adjusting for age and sex, the association was unchanged 
(adjusted OR: 2.0; 95% CI: 1.2, 3.3). Further, sex (male vs. female) was not a 
predictor of vitamin D status (OR: 1.1; 95% CI: 0.69, 1.7). Older (>12 months) 
children had a non-statistically significant 50% increased risk (OR: 1.5; 95% CI: 
0.87, 2.6) of serum 25(OH)D levels <17 ng/ml compared with younger children (6 
- 12 months). 
Stunting and vitamin D status 
A greater proportion of children who had serum 25(OH)D concentrations <17 
ng/mL were stunted than children with 25(OH)D levels ≥17 ng/mL (79.2% vs. 
58.3%, respectively) (Table 2-4). After adjusting for age and sex, children with 




with higher serum concentrations (≥17 ng/ml) (ORadj: 2.8; 95% CI: 1.6, 4.7) (Table 
2-5). In addition, boys were 1.6 times (95% CI: 1.1, 2.3) more likely to be stunted 
than girls but age was not associated with stunting (OR: 0.9; 95% CI: 0.57, 1.3).  
 
DISCUSSION 
To our knowledge this is the first study to measure vitamin D status in Ecuadorian 
children. Children who were underweight were 2.0 (95% CI: 1.2, 3.3) times more 
likely to have serum 25(OH)D levels <17 ng/ml compared to normal weight 
children. Finally, we report a novel association between lower vitamin D status and 
stunting (adjusted OR: 2.8; 95% CI: 1.6, 4.7).  
 
Reports on the association of vitamin D deficiency on stunting in young children 
not diagnosed with rickets are limited. There is evidence from adolescent studies 
to support an association between vitamin D deficiency and reduced linear growth 
112,171,172.  Among older adolescent girls (16 to 22 years), Kremer et al. found a 
positive correlation between circulating 25(OH)D and height172. In adolescents in 
Bogota, Colombia, a longitudinal study by Gilbert-Diamond et al.112 found that 
vitamin D deficiency (<20 ng/ml) was associated with impaired growth in girls but 
not in boys.  Infants whose mothers received vitamin D supplements during 
gestation showed improved birth weight and linear growth in the first year of life 
compared to infants born to non-supplemented mothers 86,108,109,173.  Vitamin D 





Defining low vitamin D status and which cutoff to use has been extensively 
debated, especially in the pediatric population23,56. Currently, there are insufficient 
data to support a specific cutoff in children. The definitions set forth by the IOM 
relate to serum levels needed to prevent rickets and demonstrate optimal bone 
mineral density23,170. The Endocrine Society Practice Guidelines definitions focus 
on levels associated with improved bone mineral density, muscle mass, and 
plateauing of PTH levels7,19.  The validity of applying the traditional cutoffs to our 
endpoints of undernutrition was unclear and thus we chose to conduct a sensitivity 
analysis to examine the consistency of the effects across a wide range of serum 
25(OH)D concentrations. These analyses suggested an optimum cutoff value for 
serum 25(OH)D of <17 ng/ml in this data set.  
 
Overall, 18.6% of children had a serum 25(OH)D level of <17 ng/ml. By contrast, 
using the cutoffs from the Endocrine Society Practice Guidelines 19, we found that 
35% of children had serum 25(OH)D levels <20 ng/ml and 46.1% were vitamin D 
insufficient (20 to <30 ng/ml). The level of deficiency is slightly higher than in 
children (2 to 5 years) in Mexico (<20 ng/ml: 24%) 154, the Patagonia region of 
Argentina (6 to 23 months) (<20 ng/ml: 24%)147, and US children (1 to 8 years) 
(<20 ng/ml: 9-11%)174. However they are similar to those from Brazil (7 to 18 years) 
(<20 ng/ml: 36.3%)149. In comparison to findings from Colombia (5 to 12 years)112, 




Colombian children (35% vs. 10.2%) but the level of insufficiency (20 to 29 ng/mL) 
is comparable (46.1% vs. 46.4%). These findings are similar to studies which 
examined vitamin D status in low SES children in the US (1 to 5 years)175 and the 
Netherlands (6 years)168. Severe deficiency, defined by the IOM as serum 
25(OH)D levels <12 ng/ml, was present in only 3.5% of children. This is similar to 
rates found in the Patagonia region of Argentina 147 (<11 ng/ml: 2.8%), Costa 
Rica151 (<12 ng/ml: 3.5%) and US children (<12 ng/ml: 1%)174.  
 
There may be several reasons for such a high level of vitamin D deficiency and 
insufficiency in Ecuadorian children. The oversampling of underweight children 
due to the weight-stratified sampling design of the original RCT might have 
resulted in a selection bias in favor of a higher prevalence of vitamin D deficiency. 
In addition, the high altitude in Quito, causes a cooler climate which leads to less 
skin exposure and cutaneous vitamin D synthesis. Further, in Ecuador, dairy 
products are not fortified with vitamin D, although there is a minor amount of 
vitamin D in margarine (2000 IU/kg). Additional dietary sources of vitamin D 
(primarily oily fish, and to a minor extent beef liver, cheese, and egg yolks) in 
children residing in the barrios are infrequently consumed.  An evaluation of food 
intake of elderly living in the same neighborhoods found minimal dietary sources 





Underweight children were twice as likely to have lower serum 25(OH)D 
concentrations (<17 ng/ml) compared to normal weight children (OR: 2.0; 95% CI: 
1.2, 3.3). Studies of low SES children in the Netherlands168, German adults176, and 
the elderly in England177 found a similar risk of lower vitamin D status in 
underweight subjects compared to normal weight. The mechanism by which this 
occurs is unclear. A logical hypothesis is that being underweight is the result of 
reduced intake of both calories and micronutrients such as vitamin D. Our findings 
suggest that improved dietary vitamin D intake may have an important impact on 
vitamin D status in the underweight population.  
 
In line with previous studies, we found that the mean 25(OH)D serum 
concentrations were higher in younger children (6 to 12 months) than older children 
(>12 to 36 months) (MD: 4.0; 95% CI: 2.7, 5.4)168,174,178–181. However, in the logistic 
regression models this was not significant (OR: 1.5; 95% CI: 0.87, 2.6).  Sex was 
not associated with vitamin D status which confirms findings in previous studies in 
young children168,175,182,183.  
 
Stunting has been repeatedly observed in the Andes184. A report by the World 
Bank found that 23.2% of Ecuadorian children under the age of 5 years are stunted 
3. We found much higher levels of stunting in our study population (62.2%), which 
is partly due to sampling in a low SES region of Quito as well as oversampling of 




Ecuador, with topographically high altitudes. Prior studies have found that stunting 
is more common at high altitude185,186. National data show that children residing at 
1,500 meters and higher are more likely to be stunted than those residing at lower 
altitudes3.  
 
We also found that boys were more likely to be stunted than girls which is 
consistent with the international literature 113,187. Although improved access to 
sanitary facilities and potable water has been reported to reduce stunting188–190, 
we did not find any association between these household SES factors and 
stunting.  
 
A strength of this study is that children’s serum 25(OH)D concentrations were 
ascertained within a narrow time period (June-July). Thus the effect of seasonality 
did not play a role in differences of vitamin D status. Other strengths include the 
large sample size and careful attention to anthropometric measurements. 
Furthermore, oversampling of undernourished children allowed us to more robustly 
assess differences between normal and undernourished groups than had we used 
a population representative sampling strategy. We believe our empiric result that 
a cutoff of 17 ng/ml, which had the strongest statistical relationship to WAZ <-1 
SD, and to HAZ <-2 SD (Supplemental Table 2-1), may be an important 





It is important to note that our study has some inherent limitations. First, the 
findings may not be generalizable to all Ecuadorian children. The weight-stratified 
nature in which subjects were recruited into the original trial resulted in 
oversampling children in the underweight category. In addition, the study 
participants live in a specific peri-urban area of Quito with lower SES than other 
parts of Ecuador. A nationally representative study would better assess the vitamin 
D status in the country and is warranted based on our results. 
 
Another limitation of this study is the lack of data on potential determinants of 
vitamin D status such as time spent outdoors, breastfeeding status, dietary 
sources, use of sunscreen, and skin pigmentation13. Moreover, it is possible that 
genetic differences contribute to differences in vitamin D status and 
polymorphisms were not tested in this study. Finally, it is important to note that the 
cross-sectional design cannot ascertain causality between undernutrition and 
lower vitamin D status and cannot rule out reverse causation. 
 
SUMMARY 
We empirically found that a cutoff of <17 ng/ml had the highest statistical 
association with underweight and stunting. In this cross-sectional analysis of poor 




18.6% of children had serum 25(OH)D levels <17 ng/ml, 35% of children with 
vitamin D levels <20 ng/ml, and 46.1% with serum levels between 20 to 29 ng/ml. 
This is higher than expected given the equatorial latitude and high altitude. Since 
there are no nationally representative data on vitamin D deficiency in the Andes, 
studies evaluating other pediatric populations in Ecuador are warranted.  
 
We found that children who were underweight were more likely to have lower levels 
of serum 25(OH)D (<17 ng/ml) than normal weight children. In addition, serum 
25(OH)D <17 ng/ml levels were strongly associated with stunting. These findings 
have important public health implications especially in low SES populations. The 
role of vitamin D in stunting should be further evaluated. Our results suggest that 
vitamin D food fortification could benefit current Ministry of Health efforts to reduce 
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Table 2-1:  Baseline characteristics of study participants stratified by 






(WAZ ≤-1)  
N=337 
Normal weight  
 (WAZ >-1) 
N=179 
Demographic and household characteristics 
Age (mo) 516  17.9 ± 7.7 17.8 ± 8.5 
      6-12  134  26.0 83 (24.6) 51 (28.5) 
      >12  382 74.0 254 (75.4) 128 (71.5) 
Sex 516    
    Male 261 50.6 174 (51.6) 87 (48.6) 
    Female 255 49.4 163 (48.4) 92 (51.4) 
Maternal education5 377    
   Illiterate  34 9.0 19 (7.7) 15 (11.5) 
   Primary  190 50.4 128 (52.1) 62 (47.3) 
   High school +  153 40.6 54 (40.2) 54 (41.2) 
Paternal education5 361    
   Illiterate  27 7.5 19 (8.0) 8 (6.5) 
   Primary  179 49.6 115 (48.3) 64 (52.0) 
   High school +  155 42.9 104 (43.7) 51 (41.5) 
Household ownership5 381    
   Own 193 50.7 123 (49.8) 70 (52.2) 
   Rent 119 31.2 79 (32.0) 40 (29.9) 
   Other 69 18.1 45 (18.2) 24 (17.9) 
Access to sanitary facilities5 380    
   Access to toilet 190 50.0 113 (45.6) 77 (58.3) 
   No access to toilet 190 50.0 135 (54.4) 55 (41.7) 
Crowding5 369 2.7 ±1.6 2.7 ± 1.5 2.6 ± 1.7 
Water source5 381    
   Potable  230 60.4 150 (60.5) 80 (60.2) 
   Non-potable 151 39.6 98 (39.5) 53 (39.8) 
Anthropometric measures     
Weight (kg) 516 9.2  ± 1.8 8.6 ± 1.5 10.2 ± 1.9 
Height (cm) 516 74.8 ± 7.6 73.6 ± 7.0 77.0 ± 8.3 
Height-for-age Z (HAZ) 
score 
516 -2.3 ± 1.2 -2.8 ± 1.0 -1.5 ± 1.0 
HAZ2     




     Mildly stunted 134 26.0 54 (16.0) 80 (44.7)  
     Stunted 321 62.2 275 (81.6) 46 (25.7)  
Weight-for-height or length 516 -0.18 ± 
1.0 
-0.63 ± 0.82 0.55 ± 0.68 
WHZ or WLZ2     
     Normal weight for height  411 79.6 235 (69.7) 176 (98.3) 
     Mildly wasted 89 17.3 86 (25.5) 3 (1.7) 
     Wasted 16 3.1 16 (4.8) 0 (0) 
Laboratory measures     
25(OH)D (ng/mL)3 516 23.2 ± 7.1 23.1 ± 7.4 23.3 ± 6.4 
     <17 ng/mL 96 18.6 74 (22.0) 22 (12.3) 
      ≥17 ng/mL 420 81.4 263 (78.0) 157 (87.7) 
iPTH (pg/mL)2,5 396 18.4 ± 
14.3 
18.4 ± 14.7 18.3 ± 13.5 
Hemoglobin (g/L) 491 12.0 ± 1.2 12.0 ± 1.2 12.2 ±1.2 
 
Footnote:  
1 All values are mean ± SD or n and percentages.  
2 WAZ, weight-for-age z score; HAZ, height-for-age z score; WHZ and WLZ, 
weight-for-height and weight-for-length z scores; 25(OH)D, 25-hydroxyvitamin D; 
iPTH, intact Parathyroid hormone. 
3 Underweight (WAZ ≤-1 SD): Includes both mildly underweight and moderately 
underweight children. 
4 To convert units of 25(OH)D from ng/mL to nmol/L multiply by 2.496. 
5 Maternal education: data available for 377; Paternal education: data available 
for 361; Household ownership: data available for 381; Access to sanitary 
facilities: data available for 380; Crowding: data available for 369; Water source: 









Table 2-2: Mean 25-hydroxyvitamin D (25(OH)D) levels based on different 
cutoff points defined by using a study specific sensitivity analysis cutoff, 
the Institute of Medicine, and the Endocrine Society Practice Guidelines 
 
 Cutoff (ng/mL) n (%) 
(N = 516) 
Mean ± S.D. 
25(OH)D (ng/ml) 
Study specific for undernutrition 
Low 25(OH)D <17  96 (18.6) 14.0 ± 2.3 
Referent ≥ 17  420 (81.4) 25.3 ± 6.0 
Institute of Medicine    
At risk of deficiency <12  18 (3.5) 10.2 ± 1.7 
Risk of inadequacy 12-19  163 (31.6) 16.8 ± 2.1 
Sufficient ≥20  335 (64.9) 27.0 ± 5.6 
Endocrine Society Practice Guidelines 
Deficient <20  181 (35.1) 16.2 ± 2.9 
Insufficient 21-29  229 (44.4) 23.8 ± 2.4 













Table 2-3: Multivariate models for predictors of vitamin D status (serum 25-
hydroxyvitamin D: <17 vs. ≥ 17 ng/ml)  
 
 
 N=516 Univariate OR 
 (95% CI) 
N=516 Multivariate OR 
(95% CI) 
WAZ1     
    Normal weight 
    (WAZ ≥-1 SD2) 
179 Reference 179 1 
    Underweight3         





Age     
    6-12 mo 134 Reference 134 1 




Sex     
    Female 255 Reference 255 1 






Unadjusted model: vitamin D status (<17 ng/ml vs ≥ 17 ng/ml = WAZ (≤-1 SD vs 
> -1 SD). 
Multivariable model adjusted for age (dichotomous) and sex. 
1 WAZ: Weight-for-age Z score.  
2 SD: Standard deviation. 








Table 2-4:  Baseline characteristics of study participants stratified by 








25(OH)D    
≥17 ng/mL 
N=420 
Demographic and household characteristics 
Age (mo) 516 18.4 ± 7.7 17.7 ± 8.1 
    6-12  134 19 (19.8) 115 (27.4) 
    >12  382 77 (80.2) 305 (72.6) 
Sex 516   
   Male 261 50 (52.1) 211 (50.2) 
   Female 255 46 (47.9) 209 (49.8) 
Maternal education 377   
   Illiterate  34 5 (7.4) 29 (9.4) 
   Primary  190 38 (55.9) 152 (49.2) 
   High school +  153 25 (36.8) 128 (41.4) 
Paternal education 361   
   Illiterate  27 4 (6.2) 23 (7.8) 
   Primary  179 34 (53.3) 145 (49.0) 
   High school +  155 27 (41.5) 128 (43.2) 
Crowding 369 2.5 ± 1.5 2.7 ± 1.6 
Household ownership 381   
   Own 193 38 (55.9) 155 (49.5) 
   Rent 119 14 (20.6) 105 (33.6) 
   Other 69 16 (23.5) 53 (16.9) 
Access to sanitary facilities 380   
   Access to toilet 190 33 (48.5) 157 (50.3) 
   No access to toilet 190 35 (51.5) 155 (49.7) 
Water source 381   
   Potable  230 38 (55.9) 121 (38.7) 
   Non-potable  151 30 (44.1) 192 (61.3) 
Anthropometric measures    
Weight (kg) 516 9.0 ± 1.6 9.2 ± 1.9 
Height (cm) 516 74.4 ± 7.0 74.9 ± 7.8 
Weight-for-age 516 -1.6 ± 0.9 -1.4 ± 1.0 
WAZ2    




     Underweight 337 74 (77.1) 263 (62.6) 
Height-for-age 516 -2.6 ± 1.1 -2.3 ± 1.2 
HAZ2    
     Not stunted  195 20 (20.8) 175 (41.7) 
     Stunted 321 76 (79.2) 245 (58.3) 
Weight-for-height or length 516 -0.26 ± 0.89 -0.21 ± 0.97 
WHZ or WLZ2    
     Normal weight for height  411 78 (81.3) 333 (79.3) 
     Mildly wasted 89 15 (15.6) 74 (17.6) 
     Wasted 16 3 (3.1) 13 (3.1) 
Laboratory measures    
25(OH)D (ng/mL)3 516 14.0 ± 2.3 25.3 ± 6.0 
iPTH (pg/mL)2,4 396 19.7 ± 15.7 18.1 ± 13.9 
Hemoglobin (g/L) 491 12.1 ± 1.0 12.0 ± 1.2 
 
Footnote:  
1 All values mean ± SD or n (%).  
2 WAZ, weight-for-age z score; HAZ, height-for-age z score; WHZ and WLZ, 
weight-for-height and weight-for-length z scores; 25(OH)D, 25-hydroxyvitamin D; 
iPTH, intact Parathyroid hormone. 
3 To convert units of 25(OH)D from ng/mL to nmol/L multiply by 2.496. 
4 Maternal education, n=377; paternal education, n=361; household ownership, 




































Crude model: HAZ (≤-2 SD vs. >-2 SD)=vitamin D status (<17 ng/mL vs. ≥ 17 
ng/mL). 











 N=516 Univariate OR  
(95% CI) 
N=516 Multivariate OR* 
 (95% CI) 
25(OH)D cutoff     
     ≥17 ng/mL 420 Reference 420 1 




 Age     
     6-12 mo 134 Reference 134 1 




Sex     
   Female 255 Reference 255 1 
   Male 261 1.6  
(1.1, 2.2) 




























Figure 2-2: Distribution of (A) serum 25(OH)D by WAZ groups (  
underweight: (WAZ ≤-1) (n=337) and  normal weight: (WAZ >-1)) (n=179) 
(B) serum 25(OH)D by HAZ groups (  stunted: (HAZ ≤-2) (n=321) and  






Supplemental Table 2-1: Results of sensitivity analysis using various 



























1 Model 1: Underweight (WAZ ≤ -1) as a predictor with varying 25(OH)D cutoffs. 














 Model 1: 25(OH)D=WAZ 
group1 





OR 95% CI P-value OR 95% CI P-value 
12  1.9 0.62, 5.8 0.27 2.2 0.71, 6.7 0.18 
13 1.1 0.49, 2.3 0.87 2.1 0.87, 4.9 0.10 
14 1.3 0.62, 2.6 0.51 2.3 1.0, 5.2 0.04 
15 1.4 0.77, 2.7 0.26 1.9 0.97, 3.5 0.06 
16 1.8 1.0, 3.0 0.04 3.1 1.7, 5.6 0.0002 
17 2.0 1.2, 3.4 0.008 2.7 1.6, 4.6 0.0002 
18 1.5 0.97, 2.4 0.07 2.2 1.4, 3.5 0.0007 
19 1.5 0.97, 2.2 0.067 2.0 1.3, 3.1 0.0010 
20 1.3 0.92, 2.0 0.13 1.8 1.2, 2.6 0.004 
21 1.4 0.96, 2.0 0.08 1.6 1.1, 2.3 0.01 
22 1.2 0.86, 1.8 0.26 1.5 1.1, 2.2 0.02 
23 1.1 0.74, 1.5 0.74 1.5 1.1, 2.2 0.02 
24 1.0 0.70, 1.5 0.93 1.4 0.98, 2.0 0.06 
25 0.87 0.59, 1.3 0.47 1.2 0.85, 1.8 0.27 
26 0.86 0.57, 1.3 0.45 1.2 0.78, 1.7 0.48 
27 0.79 0.52, 1.2 0.28 1.1 0.71, 1.6 0.76 
28 0.73 0.47, 1.1 0.17 1.0 0.69, 1.6 0.82 
29 0.73 0.46, 1.2 0.19 1.0 0.68, 1.6 0.83 




Supplemental Table 2-2: Comparison of subjects included in the 
multivariate analysis with those who are not included due to missing 





1: 25(OH)D: 25-hydroxyvitamin D; to convert units of 25(OH)D from ng/ml to 
nmol/L multiply by 2.496. 
2: WAZ: Weight-for-age z score. 
3: HAZ: Height-for-age z score. 

















Variable n Mean (SD) 
or % 




Age (mo) 377 17.9 (8.1) 139 17.8 (7.8) 0.99 
Sex 377   139    
    Female 182 71.4 73 28.6 0.39 
    Male 195 74.7 66 25.3  
25(OH)D1 (ng/mL) 377 23.3 (7.2) 139 22.8 (6.7) 0.51 
WAZ2 377 -1.4 (1.0) 139 -1.4 (1.1) 0.79 
HAZ3 377 -2.3 (1.2) 139 2.4 (1.1) 0.77 
Weight (kg) 377 9.2 (1.8) 139 9.1 (1.9) 0.65 
Height (cm) 377 74.9 (7.7) 139 74.5 (7.5) 0.66 
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Acute lower respiratory tract infections (ALRI), particularly pneumonia, are major 
global causes of mortality in children less than 5 years125,128. Nearly 1.4 million 
(19%) deaths per year are attributable to pneumonia in this age group126,128, with 
low- and middle-income countries (LMICs) accounting for 99% of all childhood 
pneumonia deaths worldwide191.  Poor nutritional status in children, which includes 
micronutrient deficiencies, is an important risk factor for severe ALRI in 
children134,191. Indeed, nutritional intervention strategies have been used to 
effectively prevent severe pneumonia81,191. Identifying additional risk factors for 
severe ALRI are important to provide evidence to target interventions to prevent 
childhood pneumonia.  
 
Vitamin D deficiency may be an important modifiable risk factor for childhood 
pneumonia because vitamin D has been shown to play an important role in 
immune function. In vitro studies have validated vitamin D’s immunomodulatory 
role in the innate and adaptive immune response by identifying a possible 
mechanism of action. Binding of toll-like receptors (TLRs) on immune cells to the 
microbial ligands causes an increased expression of the 1-alpha hydroxylase 
enzyme and the vitamin D receptor (VDR) in immune cells48. 25-hydroxyvitamin D 
(25(OH)D) is converted to the active metabolite 1,25 (OH)2D and binds to its 
nuclear receptor which in turn binds to the vitamin D response elements (VDREs) 




peptide (hCAP-18)30,43,44.  Bronchial epithelial cells produce hCAP-18, a process 
that is enhanced if there is sufficient 25(OH)D concentrations30.  In vivo studies in 
mice infected with influenza A have shown that cathelicidin treatment can decrease 
the severity of infection and viral replication192. The active vitamin D metabolite, 
1,25-dihydroxyvitamin D3, has also been shown to shift the adaptive immune 
response to a more anti-inflammatory response which can protect against 
respiratory tract infection30,47.   
 
These in vitro findings have been supported by data from observational studies.  
Mansbach et al.193 found that children <2 years with bronchiolitis who had lower 
levels of hCAP-18 (<218 ng/mL) were more likely to be hospitalized for ≥24 hours 
compared to those that had higher hCAP-18 levels (≥218 ng/mL) (OR: 5.7, 95% 
CI: 2.0, 16.2).   
 
Several epidemiological studies offer supportive evidence that vitamin D deficiency 
is associated with both the severity and incidence of ALRI. Studies in children 
diagnosed with nutritional rickets offered the first clues that vitamin D deficiency 
might be associated with ALRI135–137. A case-control study reported that 85.1% of 
hospitalized rachitic children (2 months to 2 years) were admitted to the hospital 
for ALRI compared to only 30% of control children (with no clinical signs of rickets) 
(p<0.01)136. Further, children with rickets had a significantly longer duration of 




Several case-control studies in children with severe ALRI without nutritional rickets 
also have shown evidence to support this association.  Two hospital-based 
pediatric case-control studies, one in India138 (n=80) (≤5 years) and the other in 
Bangladesh139 (n=50) (1-18 months), reported significantly lower mean serum 
25(OH)D concentrations in ALRI cases compared to healthy controls. Two 
additional hospital-based case-control studies conducted in Canada offer 
conflicting evidence140,194 although one conducted by McNally et al.140 reported 
that children admitted to the pediatric intensive care unit (PICU) for ALRI had 
significantly lower 25(OH)D levels than those admitted to the general pediatric 
ward (19.6 ± 9.6 and 34.8 ± 15.6 ng/ml, respectively), indicating that vitamin D 
status may be associated with severity of pneumonia.  
 
As the study by McNally et al.140 showed, differences in vitamin D status might 
cause variations in pneumonia severity. Increased severity at the time of admission 
to the hospital may lead to a longer duration of hospitalization. Given these 
inconsistent findings, we aimed to determine whether vitamin D status was 
associated with time to remission of respiratory signs among children hospitalized 
for pneumonia. Since the previous studies were conducted in South Asia and 
Canada, this would be the first study of its kind in Latin America. In this study, we 
aimed to assess if vitamin D deficiency (25(OH)D ≤20 ng/mL) predicts longer time 
to normalization of three respiratory signs (chest wall indrawing, tachypnea, and 




vitamin D status was associated with individual respiratory signs and differences 
in ALRI etiology. Finally, we assessed whether additional risk factors for 
pneumonia were predictive of time to remission of respiratory signs.   
 
SUBJECTS AND METHODS 
Study setting 
Study participants were children aged 2 to 59 months who were hospitalized for 
severe pneumonia at the Baca Ortiz Children’s Hospital in Quito, Ecuador and 
participated in the Ecuadorian Pneumonia and Zinc (EcuaPAZ) study 
(www.clinicaltrial.gov identifier number: NCT 00513929). Details of the study 
design have been reported previously195. Briefly, children hospitalized for severe 
pneumonia between February 2008 and April 2010 were enrolled in a randomized, 
double blind, placebo-controlled trial that assessed the effect of 20 mg of elemental 
zinc/day in two doses as an adjunct to the treatment of pneumonia with standard 
antibiotics. All children received antibiotic treatment according to national 
guidelines at the time the study was conducted196.  
 
Children with severe pneumonia were recruited from the emergency room, 
pediatric clinic, or lactation clinic and followed until they were discharged or lost to 
follow-up. Exclusion criteria included treatment with antibiotics for 24 hours prior 
to hospital admission, severe undernutrition (marasmus and kwashiorkor), 




other viral infections, pneumonia due to aspiration, complicated pneumonia, acute 
diarrhea, sepsis), and other underlying disorders (hepatic or renal disease, 
neurological disorders, or congenital abnormalities). The study used a modified 
version of the World Health Organization (WHO) definition for severe 
pneumonia196 defined as having the following respiratory signs: cough and/or chest 
wall indrawing determined by direct observation; tachypnea, determined by 
counting the respiratory rate for 60 seconds and defined as >50 breaths/minute in 
children aged 2-12 months and >40 breaths/minute in children >12 to 59 months; 
hypoxemia, determined by pulse oximeter and defined as having an oxygen 
saturation (SpO2) <90%; and at least one of the following: rales, diminished breath 
sounds, bronchial breath sounds, or pleural rub.  
 
The current study was limited to subjects who participated in the EcuaPAZ trial 
and who had a minimum of 100 µL of serum from their baseline blood draw at 
admission. 
 
Study procedures and definitions 
Trained study personnel measured the weight and height of children at enrollment. 
Height-for-age (HAZ), weight-for-age (WAZ), and weight-for-height (WHZ) or 
weight-for-length (WLZ) z scores were calculated using the 2007 WHO growth 
standards (WHO Anthro version 3.2.2, January 2011, WHO, 




underweight, stunted and wasted if their respective WAZ, HAZ, and WHZ/WLZ 
scores were ≤ -2 standard deviations (SD) below the median of the WHO child 
growth standards. 
 
Study trained physicians performed a clinical examination every six hours to 
assess respiratory signs which included hypoxemia, tachypnea, chest wall 
indrawing, and thoracic auscultations. In addition, a complete physical exam was 
done every 24 hours. Our primary outcome was remission of respiratory signs, 
defined as no longer exhibiting presenting signs for at least 12 hours. Remission 
of hypoxemia was noted if oxygen saturation (SpO2) normalized to ≥90%; 
remission of respiratory rate occurred if children normalized their respiratory rate 
(infants 2 to 12 months had ≤50 breaths/minute and children >12 to 59 months had 
≤40 breaths/minute). Time to remission of each respiratory sign was calculated 
from the time of study enrollment until the date and time remission was observed. 
For the composite outcome of remission of all three respiratory signs, the 
maximum time to remission of all three respiratory signs was used. For those 
without remission of respiratory signs, follow-up time was calculated from study 
enrollment to the date and time the child exited the hospital (whether or not they 
were discharged). Follow-up time was truncated to the 95th percentile due to a very 





The etiology of pneumonia was determined in 92.2% of subjects (n=321)197. 
Streptococcus pneumoniae and Hemophilus influenzae type b (Hib) were 
determined by whole-blood polymerase chain reaction (PCR) and other pathogens 
were determined by PCR analysis of nasopharyngeal swabs.  The etiology of ALRI 
for the analysis in this study was further categorized into two main groups: bacterial 
and viral.  
 
Laboratory analysis 
Hemoglobin concentration and plasma C-reactive protein (CRP) were measured 
at the time of study enrollment. Hemoglobin was assessed using the HemoCue Hb 
201+ assay and CRP was measured using the Dimension Clinical Chemistry 
System Flex reagent cartridge (Siemens).  The samples were subsequently 
cryopreserved in -80oC freezers until they were shipped to Boston MA for further 
analysis of 25(OH)D levels.   
 
Exposure measurement and definition: Serum 25(OH)D concentrations were 
measured at the Vitamin D Lab at Boston University School of Medicine (BUSM, 
Boston, MA). An automated enzyme immunoassay by Immunodiagnostic Systems 
Inc. (IDS-iSYS; Immunodiagnostic systems Ltd, Boldon, UK) was used to 




measured. Children with 25(OH)D levels <20 ng/mL were categorized as deficient 
while those with serum concentrations ≥20 ng/mL were categorized as sufficient23.  
 
Statistical Analyses 
Data analysis was performed using SAS 9.3® (SAS Institute Inc., Cary, NC). For 
descriptive statistics, means and SDs are presented for continuous variables and 
frequencies and percentages are shown for categorical variables. To assess 
differences due to seasonal changes in 25(OH)D levels, we categorized season 
of hospital admission into wet season (October - May) and dry season (June - 
September) to determine if season was a confounding variable or associated 
with duration of illness.  
 
Median (interquartile range [IQR]) time to remission of respiratory signs by vitamin 
D status was calculated and a Wilcoxon rank sum test was performed to test 
median differences. In univariate analyses, Kaplan-Meier curves for remission of 
all three respiratory signs were plotted stratified by vitamin D status and by nutrition 
status indicators (WAZ, HAZ, and WHZ). To determine the association between 
vitamin D status and time to remission of respiratory signs, we used Cox 
proportional hazards regression.  Potential confounders were added to the model 
separately and the change of magnitude was noted on the hazard ratio (HR) of the 




no known confounders changed the HR estimate by >10%. Potential confounders 
included: age (in months), sex, weight, height, WAZ, HAZ, WHZ, treatment group 
(placebo vs. zinc), initial oxygen saturation, initial respiratory rate, baseline 
temperature, recruitment location (emergency ward, pediatric clinic, or lactation 
clinic), breastfeeding status (ever breastfed or never breastfed), immunization 
status (complete or incomplete), CRP, hemoglobin, and SES indicators (persons 
per household, rooms per household, kitchen location (in or outside of household)).   
 
Fever at baseline was defined when children presented with a temperature ≥38oC. 
Oxygen saturation and respiratory rate were analyzed as continuous variables. 
Other risk factors analyzed were HAZ, WAZ, CRP categories, presence of 
pathogens, and bacterial versus viral etiology.  We also examined effect measure 
modification by adding variables to the model based on known risk factors for 
pneumonia duration198 and treatment failure199.    
 
A post hoc power analysis was performed using PROC POWER two sample 
survival test to have an 80% power to detect a difference in time to resolution of 
24 hours between the two vitamin D groups with a type 1 error of 0.05. The results 
of the post hoc power analysis indicate that for a hazard ratio (HR) of 1.1 to 1.2, 
the sample size would need to be close to 995 subjects to detect a significant 





The Boston University Institutional Review Board and the Ethical Committee of 
the Corporación Ecuatoriana de Biotecnología (CEB) in Ecuador approved the 
study protocol.   
 
RESULTS 
Study participants  
Of the 450 subjects who participated in the parent study, 366 had sufficient serum 
volume (≥ 100 µL) to measure their 25(OH)D concentration (Figure 3-1). Subjects 
without weight and height data (n=14) and 4 subjects who did not have complete 
follow-up time were not included in the analysis. A higher proportion of children 
who were not included in the study had up-to-date vaccination status compared to 
children who were included (p=0.0065) (Supplemental Table 3-1).  Otherwise, 
children who were included in the analysis (n=348) did not differ significantly from 
those that were not included (n=102).  
 
Of the 348 subjects with follow-up time, 296 (85.1%) were discharged from the 
hospital with normalization of all 3 respiratory signs, and 52 (14.9%) were lost to 
follow-up or left the hospital without remission of all three respiratory signs due to 
the following reasons: transferred to another health facility (n=3), left against 
medical advice (n=13), pneumonia became complicated (n=9), and discovered to 
be ineligible after enrollment due to diagnosis of congenital cardiac malformation 




remission of all 3 signs, due to limited space at the hospital.  There were 325 
(93.4%) who had remission of chest wall indrawing, 302 (86.8%) remitted on low 
oxygen saturation, and 297 (85.3%) remitted on tachypnea.  
 
Subject characteristics 
The overall mean 25(OH)D concentration of children was 21.7 ± 9.6 ng/ml. Nearly 
half of the participants (48.3%, 167/348) were vitamin D deficient (≤20 ng/ml). 
Compared to vitamin D sufficient children (>20 ng/ml), vitamin D deficient children 
(≤20 ng/ml) were younger, more likely to have been ever breastfed, and less likely 
to be up-to-date with their vaccinations (Table 3-1). Vitamin D deficient children 
(≤20 ng/ml) had a lower mean HAZ score and a lower mean CRP level than 
sufficient children.  Otherwise, children in the two vitamin D groups did not exhibit 
differences in severity of respiratory signs at baseline, sociodemographic 
characteristics, zinc or placebo supplementation in the parent study, or by season 
of hospital admission.   
 
Time to remission of respiratory signs 
The median time to recovery of all three respiratory signs was nearly 3.5 days 
(83.0 hours; IQR: 40.3, 126.7 hours). Of the three respiratory signs, hypoxemia 
took the longest to normalize (83.0 hours; IQR: 40.3, 127.4 hours) followed by 




hours, IQR: 14.2, 58.0 hours) being the fastest.  The median times to remission of 
each respiratory sign and all three respiratory signs by vitamin D status are shown 
in Figure 3-2.  The median time to remission of hypoxemia was slightly shorter 
among vitamin D deficient children (76.3 hours, IQR: 36.2, 124.6 hours) compared 
to vitamin D sufficient children (84.7 hours, IQR: 45.3, 127.8 hours); however this 
was not statistically significant (p=0.23).  There were no other significant 
differences when we compared median time to remission of all three respiratory 
signs or each individual respiratory sign by vitamin D status (Figure 3-2).  Time to 
remission of the three respiratory signs was longer in children who were 
underweight (WAZ≤-2) versus not underweight (WAZ>-2) (P=0.006) (Figure 3-3B) 
and stunted (HAZ≤-2) compared to non-stunted children (P=0.014) (Figure 3-3C). 
It was also longer in wasted (WHZ≤-2) compared to not wasted children (WHZ>-
2) but this did not reach significance (P=0.082) (Figure 3-3D). 
 
We examined the effect of vitamin D status on the normalization of 3 respiratory 
signs using Cox proportional hazard models (Table 3-3). There was no effect of 
known confounders on the exposure effect estimate (Supplemental Table 3-2). 
After adjusting for pneumonia risk factors (age, sex, treatment group from parent 
study, baseline respiratory rate, WAZ score, CRP, and breastfeeding status), we 
found no significant difference in the time to remission of all 3 respiratory signs 
between those that were vitamin D deficient and sufficient (adjusted HR: 1.2; 95% 




respiratory signs by sex (adjusted HR: 1.1; 95% CI: 0.87, 1.4), treatment group 
(HR: 1.1; 95% CI: 0.86, 1.4), or breastfeeding status (HR: 0.91; 95% CI: 0.68, 1.2). 
Younger children had a longer duration of respiratory signs (HR: 0.78; 95% CI: 
0.59, 1.0), as did underweight children (WAZ ≤-2 SD) (HR: 0.61; 95% CI: 0.43, 
0.86). Children who presented with a higher respiratory rate at baseline had a 
longer time to remission of all three of their respiratory signs (HR: 0.97; 95% CI: 
0.96, 0.99). 
 
We also found no differences in the time to remission of chest wall indrawing, 
tachypnea, or hypoxemia by vitamin D status (HR: 1.2; 95% CI: 0.99, 1.6; HR: 1.1; 




Pneumonia pathogen etiology and vitamin D status 
Of those that had pathogen etiology determined (n=321, 92.2%), the most 
common pathogens were respiratory syncytial virus (RSV) (40.8%), human 
metapneumovirus (hMPV) (18.7%), adenovirus (15.6%), parainfluenza virus type 
1 (9.7%), S. pneumoniae (bacterial) (9.1%), and Mycoplasma pneumoniae 
(0.93%).  When we compared children with bacterial versus viral infection, we 
found that vitamin D deficient children were more likely to have bacterial infection 




(OR: 1.9; 95% CI: 0.81, 4.6) (Table 3-4). We adjusted for CRP and crowding in 
our models as they were found to be confounders (i.e. when they were added to 
the model they increased the exposure (vitamin D status) effect estimate by a 
magnitude >10%). Higher CRP was associated with bacterial infection (OR: 2.6; 
95% CI: 1.1, 6.2) and children with bacterial infection were more likely to present 




In this prospective study of children aged 2 to 59 months hospitalized with severe 
pneumonia who participated in a trial of zinc as an adjunct to antimicrobial 
treatment, vitamin D status was not predictive of time to remission of pneumonia 
or individual respiratory signs.  A post hoc power analysis showed that we had an 
insufficient sample size to detect a difference between the vitamin D groups at a 
HR of 1.1 to 1.2, which may explain our null findings. The median time to recovery 
was 3.5 days. Of the three respiratory signs for pneumonia, hypoxemia 
normalization took the longest. Remission of hypoxemia was nearly 3 times longer 
than chest wall indrawing and 2 times longer than tachypnea. Breastfeeding status 
did not affect the time to remission of respiratory signs. However, younger age (2 
to 12 months), higher baseline respiratory rate, oxygen saturation, and CRP levels 
were associated with a longer time to remission of respiratory signs. Since this 
study is a secondary analysis of a trial which examined the efficacy of zinc as an 




the study arm in our models and found no differences on our outcomes in those 
children who received placebo and those that received zinc.  
 
There are limited data on the effect of vitamin D status on severity of pneumonia 
and duration of pneumonia illness.  Our study is most comparable to a study 
among newborns hospitalized for severe bronchiolitis that considered vitamin D 
status at time of hospitalization and measured clinical indicators of bronchiolitis 
severity including duration of hospitalization, lowest oxygen saturation (%) 
recorded, and a bronchiolitis severity score (BSS) - a composite score from 1 to 
12 which incorporates respiratory rate, presence of respiratory distress, oxygen 
saturation, and the presence of wheezing200.  Like our study, the mean duration of 
hospitalization was slightly lower, although not significant, in the <20 ng/ml group 
(n=14) than in the ≥20 ng/ml group (64.5 ± 13.9 hours vs. 73.8 ± 4.3 hours, p=0.52 
respectively). They did not find differences in the lowest oxygen saturation 
recorded or in the BSS clinical indicators of severity (p=0.45 and p=0.97) between 
the vitamin D groups. These findings, along with our study findings, suggest that 
among hospitalized children, 25(OH)D concentrations do not predict duration of 
pneumonia signs.   
 
This is further supported by data from two placebo-controlled, randomized trials, 
which showed that vitamin D supplementation had no impact on duration of illness 




(ages 1 to 36 months) hospitalized with pneumonia with a bolus dose of 100,000 
IU of vitamin D3, found no differences in time to remission between the 
supplemented and placebo group (mean ± SD: 4.74 ± 2.22 days vs. 4.98 ± 2.89 
days, p=0.17) 143. Another trial in India141 supplemented children daily for 5 days 
with 1000 IU for children <1 year of age and 2000 IU for children >1 year and also 
found no difference in remission of respiratory signs between the supplemented 
and placebo groups (median (IQR): 72 (48,96) hours vs. 64 (48,88) hours, p=0.33).  
 
We also explored other risk factors that might predict a longer duration of illness 
due to pneumonia. We found that children who were underweight (WAZ ≤-2) had 
a longer time to remission than those with higher WAZ scores (WAZ >-2) (HR: 
0.61; 95% CI: 0.43, 0.86). Although HAZ was not included in the model due to 
collinearity with WAZ, the Kaplan-Meier curves show that stunted children (HAZ <-
2) had a significantly longer time to remission of respiratory signs than non-stunted 
children (HAZ >-2) (Figure 3-3C). This is consistent with other studies198,201. A 
study by Moschovis et al.201 reported that stunted children had significantly lower 
remission of hypoxemia (HR: 0.74; 95% CI: 0.61, 0.89) and respiratory rate (HR: 
0.63, 95% CI: 0.52, 0.75) compared to non-stunted children.  Unlike previous 
studies, wasting was not significantly associated with duration of illness (Figure 3-
2D) (p=0.0819). However, we may not have had adequate power to detect 
significance since the EcuaPAZ parent study found a significant difference in 





Identifying baseline characteristics that may affect the duration of hospitalization is 
important, especially in resource-limited settings, as this may alter their clinical 
management198. Children 2 to 12 months of age with severe pneumonia had a 
longer time to remission of respiratory signs than older children. This finding is in 
line with previous studies examining predictors of illness duration in children 
hospitalized with pneumonia198. Hypoxia and increased respiratory rate at baseline 
were significant predictors of longer time to duration of respiratory signs. Previous 
studies have shown these two clinical symptoms to be significant independent 
predictors for treatment failure199 and two studies showed that hypoxia was 
associated with a longer time to resolution of respiratory signs198,202. The current 
findings support the evidence198199200 that pulse oximetry is an independent 
predictor of duration of illness and further add that tachypnea is associated with a 
longer duration of illness198.  
 
Several studies have suggested that vitamin D deficiency may be associated with 
different microbial etiologies of pneumonia139,140,194.  We show here that vitamin D 
deficient children were 1.9 (95% CI: 0.81, 4.6) times as likely to have a bacterial 
infection as those who were vitamin D sufficient. The number of children with 
bacterial infection was small however (n=29) compared to children who had viral 
infection (n=291). Therefore our findings are imprecise. These results do however 




infection and future studies should consider this when evaluating the role of vitamin 
D on specific infectious etiologies. These results may provide an explanation for 
the divergent results in studies which examine the role of vitamin D on children 
hospitalized with pneumonia. Further, supplementation trials should consider 
identifying the underlying etiology since a previous study found that zinc appeared 
to be beneficial for duration of illness amongst children hospitalized with bacterial 
pneumonia but had no effect on duration of illness for viral pneumonia203. However, 
actual pathogens were not identified in this study but instead elevated CRP 
concentration was used as a proxy for bacterial infection. 
 
As has been demonstrated elsewhere203,204, we found that higher CRP was 
associated with bacterial infection. Since it can be difficult to obtain the results for 
the pathogens causing pneumonia infection, a high CRP is a crude measure of 
whether pneumonia is caused by a viral or bacterial infection205. 
 
A strength of the study is that this was a prospective study which was conducted 
under a controlled clinical trial setting with close monitoring of respiratory signs 
conducted every 6 hours by study personnel. However, this may result in reduced 
generalizability to other hospital settings. There are several limitations of this study. 
Not all subjects completed the study for various reasons (left against medical 
advice, discharged early etc.) and time to remission could not be ascertained for 




children206,207 although it is unclear if 25(OH)D levels are affected by acute 
illness208.   
 
SUMMARY 
Hospitalization for ALRI in children <5 years places a substantial burden on health 
services especially in resource poor settings. Identifying evidence-based risk 
factors which affect the duration of illness are important in informing case 
management. We found no association with vitamin D status and duration of 
respiratory signs in children aged 2 to 59 months treated at a public hospital in 
Ecuador. However, we report other independent predictors of prolonged illness 
duration, including young age, stunting, underweight, respiratory rate at baseline 
and hypoxemia at baseline that may help to identify children with severe 
pneumonia in LMIC who are at risk for complications and will require more 




















Table 3-1: Baseline characteristics of study participants stratified by 












   
Age (mo)  
348 11.6 ± 9.6 14.3 ± 11.9 
    2-12 (mo) 210 102 (61.1) 108 (59.7) 
    >12-59  (mo) 138 65 (38.9) 73 (40.3) 
Female  154 68 (40.7) 86 (47.5) 
Male 194 99 (59.3) 95 (52.5) 
Weight (kg) 348 8.1 ± 2.4 8.6 ± 2.6 
Height (cm)  348 68.6 ± 11.1 71.9 ± 11.6 
WAZ2  348 -0.79 ± 1.4 -0.87 ± 1.1 
HAZ2 348 -1.6 ± 1.9 -1.3 ± 1.6 
WHZ/WLZ2 348 0.44 ± 2.5 0.01 ± 1.7 
Treatment arm 348   
       Placebo 181 81 (48.5) 100 (55.2) 
       Zinc 167 86 (51.5) 81 (44.8) 
Laboratory variables    
Hemoglobin (g/L) 348 11.0 ± 1.5 11.1 ± 1.4 
CRP (mg/dL)3 331 3.8 ± 5.9 4.3 ± 5.6 
       ≤ 4 mg/dL 221 116 (72.5) 105 (61.4) 
       >4 mg/dL 110 44 (27.5) 66 (38.6) 
SES demographics of family    
Ever-breastfed  
240 
126 (75.4) 114 (63.0) 




4.7 ± 1.5 4.9 ± 2.3 
Rooms/home3 344 2.8 ± 1.5 2.8 ± 1.4 
Crowding3.4 344 2.1 ± 1.0 2.1 ±1.1 
Presentation of respiratory signs at baseline   
Dry season5 
84 40 (24.0) 44 (24.3) 




Pulse oximetry (%) 
348 78.2 ± 6.4 78.3 ± 6.7 
Temperature (oC) 
348 37.5 ± 0.94 37.9 ± 2.3 




               2-12 mo 210 61.4 ± 7.5 60.1 ± 7.2 
               >12- 59 mo 138 56.4 ± 7.8 57.2 ± 9.5 
Presence of chest wall 
indrawing 
333 
163 (97.6) 170 (93.9) 
 
Footnote:  
1 All values are mean ± SD or n and percentages.  
2 CRP, C-reactive protein; HAZ, height-for-age z score; WAZ, weight-for-age z 
score; WHZ, weight-for-height z score; WLZ, weight-for-length z scores  
3 CRP, missing 17; n=160 for 25(OH)D ≤20 ng/mL and n=171 for 25(OH)D >20 
ng/mL; Vaccination, missing 3; n=167 for 25(OH)D ≤20 ng/mL and n=178 for 
25(OH)D >20 ng/mL; Number of persons per household, missing 4; n=166 for 
25(OH)D ≤20 ng/mL and n=178 for 25(OH)D>20 ng/mL; Rooms , missing 4; n=166 
for 25(OH)D ≤20 ng/mL and n=178 for 25(OH)D >20 ng/mL; Crowding, missing 4; 
n=166 for 25(OH)D ≤20 ng/mL and n=178 for 25(OH)D >2 ng/mL0. 
4 Crowding index defined as the number of persons per household/number of 
rooms 













Figure 3-2: Median time to remission of respiratory signs in the overall 





1 Median time to remission was truncated at the 95th percentile (n=14) 
2 Wilcoxon rank sum test p-values: Hypoxemia (p=0.1267); Tachypnea 
P=0.2285); Chest wall indrawing (P=0.3934); All respiratory signs (P=0.4569) 
3 Chest wall indrawing remission includes subjects who did not have chest wall 











Figure 3-3: Time to remission of all three respiratory signs of children 
hospitalized with severe pneumonia (N=348). A. Vitamin D deficient (≤ 20 
ng/mL) vs. vitamin D sufficient (> 20 ng/mL). B. Weight-for-age z score 
(WAZ ≤ -2 vs. WAZ>-2). C. Height-for-age z score (HAZ ≤ -2 vs. HAZ>-2) and 


























Table 3-3: Cox proportional hazard models of vitamin D status (≤20 ng/ml vs. >20 ng/ml) and normalization 
of all three respiratory signs (tachypnea, hypoxemia, and chest wall indrawing) 
 
Variable N Univariate 
HR  
95% CI HRadj 
 (model 1) 
(n=331) 
95% CI HRadj 
(model 2) 
(n=348) 




Serum 25(OH)D 348         
   >20 ng/mL 181 Ref  Ref  Ref  Ref  
   ≤20 ng/mL 167 1.2 0.94, 1.5 1.2 0.93, 1.5 1.2 0.92, 1.5 1.1 0.88, 1.4 
Sex 348         
  Females 154 Ref  Ref  Ref  Ref  
  Males 194 1.2 0.94, 1.5 1.1 0.87, 1.4 1.1 0.89, 1.4 1.1 0.89, 1.4 
Age group 348         
  >12-59 mo 138 Ref  Ref  Ref  Ref  




348 0.97 0.96,0.98 0.97 0.96, 
0.99 
0.97 0.96, 0.99 - - 
WAZ 348         
    >-2 SD 295 Ref  Ref  Ref  Ref  
    ≤-2 SD 53 0.58 0.42, 0.81 0.61 0.43, 
0.86 
0.59 0.43, 0.83 0.78 0.55, 1.1 
Treatment group 348         
   Placebo 181 Ref  Ref  Ref  Ref  
   Zinc 167 1.2 0.93, 1.5 1.1 0.86, 1.4 1.1 0.87, 1.4 1.2 0.95, 1.5 
CRP (mg/L) 331 0.98 0.96, 1.0 0.98 0.96, 1.0 - - 0.98 0.96, 0.99 
Breast feeding 348         
Ever breastfed 240 Ref  Ref  Ref  Ref  
Never breastfed 108 0.95        0.78, 1.3 0.91 0.68, 1.2 0.87 0.65, 
1.2 
   0.98 0.73, 1.3 
Oxygen 
saturation (%)  




Table 3-4: Risk factors for bacterial (n=29) versus viral (n=291) infection among 
children hospitalized with severe pneumonia in Ecuador 
 
 





320     
   >20 ng/mL  Reference  Reference  
   ≤20 ng/mL  1.4 0.64,3.0 1.9 0.81, 4.6 
Sex 320     
  Females  Reference  Reference  
  Males  0.87 0.40,1.9 0.73 0.32,1.7 
Age group 320     
  >12-59 mo  Reference  Reference  
   2-12 mo  0.63 0.29, 1.3 0.83 0.34,2.05 
Respiratory 
rate at BL 
(breaths/min) 
320 0.94 0.89,0.99 0.96 0.90,1.0 
CRP(mg/L) 306 1.1 1.0, 1.2 2.6 1.1, 6.2 
Crowding 316 0.72 0.46,1.1 0.82 0.52, 1.3 
Kitchen 316     
Inside  Reference  Reference  









Supplemental Table 3-1: Comparison of subjects included in the study analysis 
with those not included in the analysis due to missing covariates 
  Included participants Not included 
participants 
 
Variable n Mean (SD) or 
% 





Age (mo) 348 13.0 (11.0) 87 12.3 (9.5) 0.57 
Sex 348       
    Female 154 44.3 50 49.0 0.72 
    Male 194 55.7 52 51.0  
Vitamin D (ng/ml) 348 21.7 (9.6) 18 20.2 (11.0) 0.51 
WAZ  348 -0.83 (1.3) 83 -0.78 0.73 
HAZ/LAZ 348 -1.4 (1.7) 73 -1.1 (1.5) 0.09 
WHZ/WLZ 348 0.22 (2.2) 84 0.01 (1.6) 0.42 
Weight (kg) 348 8.4 (2.5) 97 8.4 (2.4) 0.84 
Height (cm) 348 70.3 (11.4) 86 70.8 (10.8) 0.69 
Treatment arm 348  102   
     Placebo 181 52.0 45 44.1 0.16 
     Zinc 167 48.0 57 55.9  
SES demographics      
Up-to-date 
vaccination 
251 72.8 86 86.0 0.007 
Not up-to-date 
vaccination 
94 87.0 14 14.0  
Ever breastfed 240 69.0 68 67.3 0.75 
Never breastfed 108 31.0 33 32.7  
Persons/household 344 4.8 (2.0) 101 5.2 (2.3) 0.13 
Rooms/household 344 2.8 (1.4) 100 2.6 (1.4) 0.34 
Crowding index 344 2.1 (1.1) 100 2.4 (1.8) 0.08 
Presentation of respiratory signs    
Dry season 84 24.1 15 17.2 0.17 
Wet season 264 75.9 72 82.8  
Respiratory rate (BL) 
(breaths/minute) 
348 59.2 (8.1) 102 58.4 (8.0) 0.37 
Oxygen saturation 
(BL) (%) 
347 78.3 (6.6) 102 77.2 (7.3) 0.17 
Temperature (oC) 347 37.7 (1.8) 102 37.5 (0.89) 0.12 
Laboratory variables 
CRP (mg/L) 331 4.0 (5.7) 94 4.2 (5.1) 0.79 




Supplemental Table 3-2: Change in the exposure effect estimate (hazard 
ratio and confidence width) based on adding potential confounders to the 
crude model (DGRP= Time to remission of 3 respiratory signs*censor). 















(Dgrp20=remission of 3 
respiratory signs) 
1.2 0.98 1.5 No   0.56 
+ Sex (M vs. F) 1.2 0.97 1.5 No 1.1 0.55 
+ Age (continuous) 1.3 1.0 1.6 No 5.3 0.60 
+ Age (categorical) 1.2 0.99 1.6 No 1.8 0.57 
+ Weight 1.3 1.0 1.6 No 4.3 0.59 
+ Height  1.3 1.0 1.6 No 5.6 0.61 
+ HAZ 1.2 0.94 1.5 No 3.1 0.55 
+ WAZ  1.2 0.95 1.5 No 1.7 0.52 
+ Treatment arm (zinc 
vs placebo) 
1.2 0.96 1.5 No 3.4 0.54 
+ HB  (g/L)  1.2 0.98 1.5 No 0.74 0.56 
+CRP (mg/L)  1.3 0.99 1.6 No 2.5 0.59 
+ vaccination grp 
(complete vs. 
incomplete) 
1.2 0.99 1.6 No 1.3 0.57 
+ Breastfeeding (ever 
vs never) 
1.2 0.97 1.5 No 0.82 0.56 
+PMN 1.3 1.0 1.6 No 6.5 0.61 
+ lymphocyte 1.3 1.0 1.6 No 4.7 0.60 
+ Monocyte 1.3 1.0 1.6 No 2.8 0.59 
+ Eosinophils 1.3 1.0 1.6 No 4.1 0.62 
+ Basophils 1.3 1.0 1.6 No 5.1 0.62 
+Ward (ER vs clinic vs 
lactation clinic) 


















+Season (wet vs. dry) 1.2 0.99 1.6 No 1.1      0.56 




1.5 No 3.3 0.54 




1.5 No 2.5 0.54 
+Respiratory rate at BL  1.3 1.0 1.6 No 6.1 0.60 
+Oxygen saturation at 
BL (%)  
1.2 0.9
3 
1.5 No 4.6 0.53 




1.5 No 0.49 0.57 
+presence of bronchial 




1.5 No 2.4 0.54 




1.5 No 0.90 0.55 
+Whistle (yes vs.no) 1.2 0.9
7 
1.5 No 0.49 0.55 
+Diagnosis (pneumonia 
vs, very severe) 
1.3 1.0 1.6 No 3.6 0.59 
+diminished breath 
sounds (yes vs. no) 
1.2 0.9
7 








Supplemental Table 3-3: Cox proportional hazard models of vitamin D status (≤20 ng/ml vs. >20 ng/ml) and 
normalization of individual respiratory signs 
 
 






Variable N HR 95% CI HR 95% CI HR 95% CI 
Serum 25(OH)D 348       
   >20 ng/mL  1  1  1  
   ≤20 ng/mL  1.2 0.99, 1.6 1.1 0.83, 1.4 1.2 0.95, 1.5 
Sex 348       
  Females  1  1  1  
  Males  1.1 0.90, 1.4 1.1 0.89, 1.4 1.1 0.89,1.4 
Age group 348       
    > 12-59 mo  1  1  1  
   2-12 mo  0.95 0.73, 1.2 1.2 0.88, 1.5 0.76 0.58, 1.0 
BL Respiratory 
rate  (breaths/min) 
348 0.97 0.96, 0.98 0.97 0.95, 0.98 0.97 0.96,0.99 
WAZ 348       
    >-2 SD  1  1  1  
    ≤-2 SD  0.65 0.47, 0.89 0.58 0.41, 0.82 0.61 0.43,0.86 
Treatment group 348       
   Placebo  1  1  1  
   Zinc  1.1 0.85, 1.3 1.2 0.97, 1.6 1.1 0.86,1.4 
CRP (mg/L) 331 0.99 0.97, 1.0   0.98 0.96, 1.0 
Breast feeding 348       
Ever breastfed  1  1  1  







VITAMIN D DEFICIENCY IN ECUADORIAN CHILREN 
In the community-based study, we found that 35.1% of children were vitamin D 
deficient (<20 ng/ml), and 44.4% were insufficient (20-29 ng/ml). This occurred 
despite their residing at high altitudes and equatorial latitudes. The prevalence of 
deficiency and insufficiency in the children sampled is slightly higher than other 
pediatric populations in Latin America (Figure 1-9). It is also higher than the 
prevalence of vitamin D deficiency (<20 ng/ml) found in a study conducted among 
the elderly residing in the same peri-urban neighborhoods155. That study found that 
only 9% of elderly women and 19% of elderly men were vitamin D deficient155. In 
contrast, a nationally representative survey among the elderly in the Ecuadorian 
Andes152, found that 21.6% of the elderly were vitamin D deficient (<20 ng/ml), and 
46.2% were insufficient (20-29 ng/ml). 
 
The weight-stratified oversampling of underweight children likely contributed to the 
elevated prevalence of low vitamin D status in this study population. This suggests 
that there is a need to systematically determine the magnitude of vitamin D 
deficiency among all young (<5 years) Andean children.  The findings of this 
research also frame the question: what are important risk factors for vitamin D 





To better assess the vitamin D status of Ecuadorian children, a population level 
survey is required.  A cross-sectional study, which collects information on risk 
factors for vitamin D, would provide useful evidence. Ecuadorians are racially 
diverse and have a variety of skin tones. Darker skin tones, and concomitant high 
levels of melanin, can decrease the potential to synthesize vitamin D28. The 
nationally representative survey among the elderly in the Ecuadorian Andes, 
however, found that the indigenous population was at greater risk for vitamin D 
deficiency than darker skin-toned Ecuadorians152. Therefore, collecting information 
on ethnic background is important when evaluating vitamin D status in Ecuador. 
Moreover, future studies should look at child-rearing practices as potential risk 
factors for vitamin D deficiency in the Andes. Because it is culturally acceptable to 
carry young children in covered carriers on the backs of mothers - causing the child 
to potentially receive less exposure to sunlight – this practice may be an important 
risk factor for vitamin D deficiency in the Andes. Breastfeeding rates have 
increased in Ecuador75 and are an important risk factor for vitamin D deficiency as 
there is virtually no vitamin  D found in breastmilk209.  Also, air pollution, which is a 
significant problem in Ecuador210,211, especially due to vehicle exhaust emission212, 
is important to consider as a risk factor for vitamin D deficiency in children since 
air pollution is known to absorb UVB rays and thereby limit cutaneous synthesis of 
vitamin D. Other risk factors which are important to assess include: amount of time 
spent outdoors between 7 am to 4 pm10 (some studies have used hours spent 




Tanner scores to assess skin pigmentation28; rural vs. urban residence152; and 
maternal education and other SES status indicators175.  
 
VITAMIN D AND GROWTH AMONG ECUADORIAN CHILDREN 
 
IMPERATIVE TO FURTHER INVESTIGATE THE EFFECT OF VITAMIN D ON 
STUNTING  
The key finding in this analysis is that children with lower vitamin D status (<17 
ng/ml) were 2.8 times more likely to be stunted than children with higher vitamin D 
levels.  In our models, we were only able to adjust for age and sex. As discussed, 
SES variables were only available for a sub-sample of subjects in the study and 
therefore we could not control for these in our models. For example, low maternal 
education is a risk factor for stunting in children213, and low maternal education 
may be associated with low vitamin D status168. Adding potential confounding 
variables, such as maternal education, may have explained some of the 
association between vitamin D status and stunting and could thus decrease the 
strength of the association between vitamin D status and stunting.    
 
Without potential confounders for all subjects to control for in our models, the 
association between low vitamin D status and stunting could appear stronger than 
actually exists. Therefore, we cannot rule out that there may be residual 
confounding that we were not able to control for. There are many risk factors for 




Common risk factors for stunting include: malnutrition, maternal education, 
infectious diseases (such as diarrhea and pneumonia), poor access to sanitary 
facilities and poor hygiene, crowding, birth spacing, poverty and lack of 
breastfeeding.  Future studies should ensure that risk factors for stunting are 
collected for all study subjects. This would allow for studies to control for multiple 
confounders which would provide a better assessment of the independent effect 
of vitamin D status on stunting. 
 
Also, the results are based on a cross-sectional analysis, and causal inferences 
cannot be made. However, the findings that HAZ scores of children with low 
vitamin D status at baseline remain lower than HAZ scores of children with higher 
vitamin D status, over a 50-week follow-up period, offer further support for the 
cross-sectional association between vitamin D status and stunting (Appendix 2; 
Figure A2-2 and Figure A2-3).  This prospective anthropometric analysis also has 
some limitations since baseline 25(OH)D concentrations were used.  Baseline 
25(OH)D concentrations may change over a 50-week follow-up period in children 
and 25(OH)D levels have been shown to vary over time in adolescents216.  A 
preliminary analysis in a subsample of children (N=396), which compared baseline 
25(OH)D with measurements of 25(OH)D concentrations at the last 
anthropometric visit (50 weeks later), found that 72% of children in the ≥17 ng/ml 
category remained in this category at the end of this study (Table A2-3). However 




we plan to use the baseline and endline (visit 6) 25(OH)D concentrations in 
children to determine if the change in 25(OH)D is associated with changes in 
anthropometric measurements in children.   
 
Additional studies are needed to assess the association between vitamin D and 
stunting. Supplementation trials would be an important future direction.  Although 
there are two studies107,108 in infants (<1 year) which showed that vitamin D 
supplementation was associated with improved HAZ scores, these studies did not 
sample malnourished children specifically, even though they were conducted in 
countries with a high prevalence of malnutrition. It is crucial to discern whether the 
benefits of vitamin D supplementation on HAZ manifest in children <5 years of age 
and not just among infants. Further, a key question that needs to be addressed is 
whether vitamin D can improve HAZ scores after stunting develops.  
 
An important next step is to conduct high quality supplementation trials, with 
varying doses of vitamin D, among stunted children, to assess if vitamin D has a 
beneficial impact on stunting and to determine what dose of vitamin D has the 
greatest impact on stunting. One treatment arm should have at least 1000 IU/day 
and an additional treatment arm should include vitamin D and calcium 
supplementation since there is some evidence to suggest that supplementation 
with both is beneficial for growth101. The serum 25(OH)D concentration should also 




anthropometric measurements should be collected throughout the study period. 
These trials would be especially important in the <5 year age group, with a special 
emphasis on the first 1000 days, because children in this life stage are at the 
greatest risk for growth faltering103,113.  
 
UNDERWEIGHT: A POTENTIAL RISK FACTOR FOR VITAMIN D 
DEFICIENCY 
In this study, we also found that underweight children were twice as likely to have 
lower vitamin D status (<17 ng/ml) than normal weight children.  We dichotomized 
weight status as underweight (WAZ ≤-1) and normal weight (WAZ>-1) because 
there were virtually no children who were overweight or obese. An additional study 
in a pediatric population, which investigated underweight as a risk factor for vitamin 
D deficiency, found that among low SES 6 year old children, being underweight, 
rather than overweight and obese, was a significant risk factor for vitamin D 
deficiency (25(OH)D <20 ng/ml) when compared to normal weight children 
(Underweight: OR: 2.20; 95% CI: 1.51, 3.21; Overweight: OR: 1.03; 95% CI: 0.80, 
1.31; Obese: OR: 1.45; 95 CI: 0.97, 2.18)168.  
 
Due to the rising obesity epidemic, the vitamin D literature has focused primarily 
on investigating the association between vitamin D and obesity in 
children112,172,178,217,218.  Several studies investigating the association of vitamin D 




categorized them with normal weight children, or analyzed BMI or WAZ as a 
continuous variable112,172,178,182,183,218.  The findings from the current work indicate, 
however, that being underweight is an important risk factor for low vitamin D status 
and must not be overlooked - especially when conducting studies among children 
with low SES.  
 
From our study, it is unclear why underweight children are at greater risk for lower 
vitamin D status. The logical explanation is that they are consuming less food, 
causing both underweight and lower vitamin D status to co-occur.  Information on 
dietary intake was not collected in the context of this study, which is a limitation of 
the study design.  There is evidence from a study in the elderly22, who resided in 
the same peri-urban neighborhoods, and the National Nutrition Survey ENSANUT-
201275, to support the assumption that the diets of Ecuadorian children contain 
very little vitamin D. 
 
 The dietary intake of vitamin D may be lower among underweight children 
compared to normal weight children.  Since margarine is fortified with vitamin D in 
Ecuador17,18, the use of margarine may be the reason for the higher vitamin D 
status in normal weight children compared with underweight children. A study in 
Belgium found that children with the highest tertile of intake of ‘margarine and 
cooking fats’ were less likely to be vitamin D deficient (<20 ng/ml) compared to 




additional studies should assess dietary intake to better understand if these 
differences in vitamin D status between underweight and normal weight children 
are due to dietary intake. Specifically, examining margarine intake, fish and 
shellfish intake14, consumption of eggs and meats which naturally contain small 
amounts of vitamin D19, and breastfeeding status182,209 can better assess if the 
differences found between the two weight groups are due to differences in dietary 
consumption of vitamin D. 
 
Further, underweight children may be at greater risk for vitamin D deficiency due 
to other unknown risk factors.  It is unclear if being underweight decreases the 
concentration of the precursor to vitamin D synthesis, 7-DHC, which would limit 
the ability of cutaneous vitamin D synthesis. A decrease in 7-DHC content in 
epidermal and dermal skin in the elderly (aged 77 to 82 years) has previously been 
shown219. This was found to be associated with a nearly two-fold decrease in 
previtamin D3 production when compared to 8 to 18 year olds who had higher 
cutaneous concentrations of 7-DHC. There may potentially be a similar decrease 
in the 7-DHC in undernourished children.  This may be an important consideration, 
which has not been investigated, and future studies should examine this.  
 
FUTURE WORK AND ANALYSIS 
The next steps are to prospectively determine the association of vitamin D status 




that there are differences in growth patterns in WAZ and HAZ based on baseline 
vitamin D status.  When baseline 25(OH)D was used to predict changes in WAZ 
scores over a 50-week follow-up period (Appendix 2: Figure A2-4, Figure A2-5 
and Table A2-2), the change per year in children with serum 25(OH)D levels ≥17 
ng/mL is minimal at 0.05 ± 0.03, whereas the change per year in the <17 ng/mL 
category is higher (0.22 ± 0.06) (after adjusting for baseline age, baseline WAZ 
score, sex, treatment arm from the original RCT, and an interaction term between 
vitamin D status and treatment arm) allowing for children in the lower vitamin D 
status category to catch-up. The higher rate of gain in WAZ in children with lower 
25(OH)D concentrations (<17 ng/ml) are consistent with findings by Eckhardt et 
al.105 who showed that the WAZ scores were lower in infants born to mothers with 
25(OH)D levels <12 ng/ml compared to infants born to mothers with higher levels 
(≥12 ng/ml). Like the findings in our analysis, the differences in WAZ between the 
two vitamin D categories were no longer significant by the first year of life. It has 
been suggested that low vitamin D deficiency may be an independent predictor of 
weight gain172, however the reasons for this observation are unclear at this time. 
 
An important next step in the future analysis of this data is to include body 
composition analysis, which are available for children who participated in this 
study.  Body composition analysis was measured by bioelectrical impedance, 
which may show erroneous results in malnourished children with edema, or 




an estimation of the changes in fat mass and fat free mass in children in the two 
vitamin D groups may offer some insight as to whether the changes in WAZ in 
children with low vitamin D status are due to increases in fat mass.  
 
VITAMIN D AND PNEUMONIA 
 
THE RELATIONSHIP BETWEEN PNEUMONIA AND VITAMIN D STATUS IS 
UNCLEAR 
In the current work on vitamin D and children hospitalized with pneumonia, vitamin 
D status had no effect on the duration of illness due to pneumonia. There remains 
a need for additional studies to better assess the effect of vitamin D status on 
duration of illness or other clinical indicators of pneumonia severity, as our study 
was underpowered.  The current study collected information on several risk factors 
for severe pneumonia221 which included crowding, immunization status,  
breastfeeding status, nutritional status, and whether kitchens were inside or 
outside households as a proxy measure for indoor air pollution. Future studies 
should assess indoor air pollution further as exposure to biomass fuels, smoke 
from cooking, and exposure of children to cigarette smoking are known risk factors 
for severe pneumonia221. Also, premature birth or low birth weight, specific 
information on exclusive breastfeeding, concomitant illness (e.g. HIV infection), 
maternal education, and poor access to healthcare would be additional risk factors 





This study measured duration of respiratory signs as a clinical indicator of 
pneumonia severity. Future studies should consider additional clinical outcomes 
of pneumonia severity in addition to duration of pneumonia illness. These include 
treatment failure199,202, need for mechanical ventilation202, need for and length of 
oxygen supplementation222, and admission to the PICU versus general pediatric 
ward140.    
 
As discussed, in vitro studies have shown increased production of cathelicidin due 
to sufficient vitamin D levels43,44.  Cathelicidin, and other antimicrobial peptides, 
are produced all along the upper and lower respiratory airways and offer one of 
the first mechanisms of defense against invading pathogens223. Therefore, there 
may be differences in pathogen susceptibility due to vitamin D status as children 
with lower circulating 25(OH)D levels are believed to be less able to produce 
cathelicidin38,43,223. Since our data suggest that lower vitamin D status is associated 
with an increased risk for bacterial infection, future studies, which consider the 
effect of vitamin D status on clinical outcomes of pneumonia, must examine the 
underlying etiology. This will help to provide better insight as to whether vitamin D 






PUBLIC POLICY IMPLICATIONS 
Given that we found a high prevalence of vitamin D deficiency (35.1%, <20 ng/ml) 
and insufficiency (44.4%, 20-29 ng/ml), the Ministry of Health of Ecuador should 
consider conducting a nationally representative survey in the pediatric population. 
This will enable Ecuador to detect sub-populations that are at most risk for vitamin 
D deficiency. A national vitamin D fortification program, especially the dairy supply, 
should be investigated as a low-cost means to deliver vitamin D to the entire 
Ecuadorian population.  Vitamin D fortification of the dairy supply has been shown 
to be one of the most effective fortification means, to convey modest increases in 
25(OH)D levels in populations such as in the United States and Canada25. Since 
cereal is the main component in the Ecuadorian diet, it may also make sense to 
consider cereal fortification. Further, because Ecuador does not have 
recommended dietary intakes for vitamin D, these should be stipulated for each 
life stage. 
 
Although the current research provides some evidence that vitamin D may be an 
important modifiable risk factor, it is still premature to recommend supplementation 
as a means to improve stunting. Stunting has been repeatedly observed in the 
Andes3,184. In Ecuador, the current estimates of stunting in children <5 years are 
25.3%75. Given that the Ministry of Health has made efforts to decrease 




for supplementation trials that can better discern the role that vitamin D plays on 
growth in young children.   
 
Even beyond the Ecuadorian context, research on the effects of vitamin D and 
growth (both HAZ and WAZ) in young children is very much lacking110. In the effort 
to find low cost interventions to lower stunting rates, especially so they can be 
applicable to low-and-middle income countries, it is imperative to prioritize 
research that provides a better understanding of the role of vitamin D on growth 
and pneumonia, especially in undernourished children.  
 
Finally, the current work shows that undernourished children are at risk for longer 
duration of pneumonia illness.  The current treatment guidelines for pneumonia 
should consider a more aggressive plan for treatment of undernourished children. 
This is especially crucial since undernourished children are at an increased risk for 
mortality from pneumonia128. Beyond the impact on child health, pneumonia 
remains a primary reason for hospital admission of children, and the medical costs 
can be substantial224. Reducing duration of hospitalization due to pneumonia 
would also be economically beneficial to both the individual families and 






This is the first study to determine the prevalence of vitamin D deficiency and 
insufficiency in children under 5 years in the Andes.  The high prevalence of vitamin 
D deficiency indicates that children living in the Andes are susceptible to vitamin 
D deficiency despite abundant sunshine. A national survey among young children 
in Ecuador is warranted to determine the magnitude of vitamin D deficiency and 
assess risk factors, some of which may be specific to Ecuador.  
 
The current work offers new insight on the effect of vitamin D on growth outcomes 
among undernourished children aged 6 to 36 months. Children with low vitamin D 
status are more likely to be stunted and further research is required to determine 
if vitamin D can be used as a low cost intervention to improve growth in children 
under 5 years of age. Further, children who are underweight may be at greater risk 
for vitamin D deficiency than children who are normal weight. The findings from 
the current work should be used as a platform to conduct high quality prospective 
supplementation trials to better understand the role that vitamin D plays on 
improving growth. 
 
The effect of vitamin D status on the duration of pneumonia illness, as a clinical 
indicator of pneumonia severity, is inconclusive since the study was underpowered 
to detect a difference in the duration of pneumonia illness between vitamin D 




answering given that pneumonia is the primary cause of death in children. Further 
studies are required to elucidate the impact of vitamin D status on the duration of 

























 A well-established model1 which involves exposing clear borosilicate 
ampoules containing 7-dehydrocholetsterol (7-DHC) in ethanol on an hourly 
basis throughout the day to measure 7-DHC conversion to previtamin D3 and 
vitamin D3 exists. An experiment was carried out from November 2011 to mid-
December 2011. 
OBJECTIVES 
 This was carried out to determine whether conversion of 7-DHC occurs for a 
longer time period than from 7 am to 3 pm at the equator and higher altitude 
(Quito, Ecuador). This was also compared to similar experiments performed in 
Boston, MA during the vitamin D winter and Saudi Arabia to note differences 
in latitude and altitude.  
METHODS  
Ampoules containing 7-DHC were placed one at a time for one hour from 7 am 
to 5 pm to note the percent conversion of 7-DHC to previtamin D3 and vitamin 
D3 in Quito, Ecuador. Previtamin D3 and vitamin D3 concentrations were 
ascertained using High-performance liquid chromatography (HPLC). 
RESULTS 
 Figure A1-1 shows the % conversion of 7-DHC to previtamin D3 and D3 during 




Arabia and Boston USA as well as the % conversion right before the summer 
solstice in Boston (June 20th 2011).  As can be seen, the conversion of 7-DHC 
occurs predominantly between 7 am and 3 pm in all three regions and 
markedly drops off at 4 pm.  The % conversion is highest in Quito at nearly 
every time point when compared to Saudi Arabia (presumably because of the 















Figure A1-1: % conversion of 7-DHC to previtaminD3 and vitamin D3 
from ampoules containing 7-DHC in ethanol. Ampoules were exposed 
to sunlight on an hourly basis from 7 a.m. to 5 p.m. in Quito Ecuador, 
Boston MA and Saudi Arabia during the last week of November 2011 
and early December 2011. Also, ampoules were exposed to sunlight in 





 In November in Boston, MA, during the so called “vitamin D winter”, no 























































Boston, MA (Nov. 2011)




throughout the day on an hourly basis. In contrast, Quito has a high % conversion 
of 7-DHC to photoproducts. This is higher than the % conversion to photoproducts 
in Saudi Arabia performed several days later and during the summer months in 
Boston.  
CONCLUSION 
 Although Quito experiences 12 hours of daylight per day, there is no production 
of vitamin D after 4 pm which confirms that vitamin D can only be produced 




















IMPACT OF LOW VITAMIN D ON ANTHROPOMETRIC INDICATORS OF 




Subjects for this study participated in a larger randomized placebo-controlled trial, 
the Vitamin A and Zinc Prevention of Pneumonia (VAZPOP) study in Quito, 
Ecuador. Children, aged 6 to 36 months who resided in 5 peri-urban low-
socioeconomic status neighborhoods, were recruited in four sequential blocks. 
Each block began in June to July of each year between 2000 to 2003 and lasted 
for 50 weeks.  Between 600 to 660 children were recruited in each block for a total 
of 2581 children. To participate in VAZPOP, children had to be between 6 to 36 
months and reside in one of the five neighborhoods for at least 1 year. Children 
who had taken micronutrient supplementation in the 3 months prior to the study, 
or with clinical evidence of vitamin A deficiency (e.g. xerophthalmia) were 
excluded.   
 
Children were selected to participate in the study in a weight-stratified manner with 
between 200 and 220 children in each of the following weight-for-age z (WAZ) 
score strata: clearly underweight (WAZ ≤-2), mildly underweight (-1≤ WAZ >-2), 




Human Development reference growth curves (obtained from Epi-Info 2002 
software Centers for Disease Control, Atlanta, Georgia, USA). Children were 
enrolled from each of the 5 areas in a proportional fashion so that 40 children in 
each of the 5 sites filled each WAZ strata. 
 
Within each weight strata children were randomized to one of four treatment arms: 
12.5 mg of elemental zinc (zinc sulfate) daily, 10,000 IU of vitamin A per week, 
zinc and vitamin A, or placebo. 
 
Children who participated in the final block of VAZPOP and had at least 100 µL of 
serum were eligible to participate in this study. There was insufficient serum from 
blocks 1 to 3 to include in this analysis. 
 
Anthropometric Measurements 
The current analysis used anthropometric measures carried out by trained study 
personnel at baseline and at 5 subsequent measures made every 10 weeks.   
Anthropometric devices were calibrated for accuracy by the Instituto Ecuatoriano 
de Normalización (INEN) throughout the course of the study. Length was 
measured in children <24 months using a horizontal foot board and height was 
measured using a calibrated scale in children ≥24 months using non-distensible 
plastic tape fixed onto a vertical board. Height and length were measured to the 




Health-o-meters balance scale (Webb City, Iowa, MO, USA).  Changes in 
anthropometric measurements were modeled based on continuous 
measurements of HAZ and WAZ.  Stunting and underweight were defined as 
having a HAZ ≤-2 and WAZ ≤-2 respectively.   
 
Biochemical Analysis 
Blood samples were collected by venipuncture using trace element free tubes 
(Sarstedt AG, Nümbrecht, Germany). After complete blood counts were 
measured, the serum aliquots were cryopreserved at -80oC until they were 
transported to Boston, MA. The serum 25(OH)D measurements were quantified at 
the Vitamin D Lab at Boston University School of Medicine (BUSM, Boston, MA) 
using an automated enzyme immunoassay developed by Immunodiagnostic 
Systems Inc. (IDS iSYS; Immunodiagnostic systems Ltd, Boldon, UK). This assay 
uses an ester magnetic particle chemiluminescence immunoassay (CLIA) 
technique.  The sensitivity of the assay was 6 ng/ml. 
 
Vitamin D status 
The traditional cutoffs used by the Institute of Medicine23 and the Endocrine 
Society Practice Guidelines19 focus on 25(OH)D concentrations that prevent 
rickets23, optimize bone mineral density19, and prevent secondary 




these, a sensitivity analysis was conducted to determine the most predictive cutoff. 
For the sensitivity analysis a univariate logistic regression was carried out with 
25(OH)D cutoffs changing from 12 to 30 ng/ml in 1 ng/ml increments. A cutoff of 
17 ng/ml was found to be most strongly associated with our outcomes of HAZ and 
WAZ and therefore we defined low vitamin D status as serum 25(OH)D 
concentrations <17 ng/ml.   
 
We used baseline vitamin D status in our models to determine the effect of vitamin 
D status on the change in anthropometric measures over time.   
 
Statistical analysis 
We looked for differences in HAZ and WAZ at each time point by plotting the mean 
values and corresponding 95% confidence intervals (CI) by vitamin D status and 
treatment arm. Differences in means by vitamin D groups at each visit were tested 
using student t-test or ANOVA, as appropriate.  
 
Linear mixed effects models were employed to estimate changes in HAZ and WAZ 
anthropometric measures by vitamin D status225 adjusted for potential 
confounders. A separate model was conducted for each anthropometric outcome. 
Time was included as a linear predictor in months of follow up. We explored the 
functional form of time by fitting both a linear and a quadratic model to see which 




(and time squared for quadratic models), and an interaction between time and the 
vitamin D categories (as well as time squared in quadratic models). We ran mixed 
effects models with random intercept only as well as random intercept and random 
slope and compared the Akaike information criterion (AIC) scores. The AIC scores 
were lower in the models which employed the random intercept and random slope 
so we used this method for all our models.  Unstructured variance-covariance 
matrixes were used for these random effects. In adjusted models, baseline age, 
sex, treatment arm that children were randomized to in the parent RCT, baseline 
HAZ for the models measuring changes in HAZ models, and baseline WAZ for the 
models measuring changes in WAZ.  An interaction term between randomization 
arm and vitamin D status was also included in the adjusted models.   
 
To determine if there was a correlation between 25(OH)D measurements obtained 
at baseline with 25(OH)D measurements obtained at the last anthropometric visit, 
we estimated a Pearson correlation for subjects who had both baseline and endline 
25(OH)D measurements to determine if 25(OH)D concentrations at baseline were 
significantly correlated with 25(OH)D at the last anthropometric visit.  We also 
categorized children on whether they remained in the same vitamin D categories 
(<17ng/ml or ≥17 ng/ml). 
 
The Boston University Institutional Review Board and the Ethical Committee of 






Table A2-1: Baseline characteristics of children ages 6-36 mo stratified by 
vitamin D status (<17 ng/ml vs ≥ 17 ng/ml) in children (N=515)  
 
Characteristic N 25(OH)D <17 ng/ml 
Mean ± SD or % 
(n=96) 
25(OH)D ≥17 ng/ml  
Mean ± SD or % 
(n=419) 
Sex 515   
   Female 254 46 (47.9) 208 (49.6) 
   Male 261 50 (52.1) 211 (50.4) 
Age 515 18.4 ± 7.7 17.8 ± 8.1 
    6-12 mo 133 19 (19.8) 114 (27.2) 
   12-36 mo 382 77 (80.2) 305 (72.8) 
HAZ1 515 -2.2 ± 0.89 -1.8 ± 1.0 
   Not stunted 
   (HAZ >-2) 
294 36 (37.5) 258 (61.6) 
   Stunted  
   (HAZ ≤-2) 
221 60 (62.5) 161 (38.4) 
WAZ1 515 -1.8 ± 0.78 -1.5 ± 0.95 
   Not underweight 
   (WAZ >-2) 
353 57 (59.4) 296 (70.6) 
   Underweight 
   (WAZ ≤-2) 
162 39 (40.6) 123 (29.4) 
Treatment arm 515   
Placebo 123 32 (33.3) 91 (21.7) 
Vitamin A 132 22 (22.9) 110 (26.3) 
Zinc 135 21 (21.9) 114 (27.2) 
Vitamin A + zinc 125 21 (21.9) 104 (24.8) 
 
Footnote: 











Figure A2-1: Study profile of the number of subjects at each 
anthropometric visit by vitamin D category (25(OH)D <17 ng/ml and ≥17 
ng/ml) and the number of subjects lost to follow-up 
 
 
     






419 344 75 96
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453 370 83 62
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462 375 85 53
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472 384 88 43
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484 394 90 31
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Figure A2-3: Quadratic linear mixed effect model showing predicted 
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Figure A2-5: Linear mixed effect model showing predicted trajectory of 


























Table A2-2: Change in WAZ anthropometric measures in children aged 6-36 







1 Mean ± SD  
2 Mean ± SE 
3 adjusted for baseline age, sex, baseline WAZ, treatment arm, and interaction 





























Baseline  WAZ1 -1.5 ± 1.0 -1.8 ± 0.78  
Change in WAZ/yr2 0.05 ± 0.03 0.22 ± 0.06  
    Unadjusted difference(95% CI) Reference 0.17 (0.04, 0.30) 0.01 




Table A2-3: Vitamin D status (<17 ng/ml vs ≥17 ng/ml) of children using 
serum 25(OH)D samples at the last anthropometric visit (visit 6) versus 




































25(OH)D ≥17 ng/ml 
n (%) 
25(OH)D <17 ng/ml 
n (%) 
25(OH)D ≥ 17 ng/ml 285 (72.0) 44 (11.1) 
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